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Barrett’s esophagus (BE) is a metaplastic condition where normal squamous 
epithelium of the esophagus is replaced with columnar epithelium which contains 
goblet cells. Radiofrequency endoscopic ablation (RFA) of BE is a relatively new 
procedure, with already proven safety and efficacy profile, in the complete 
eradication of BE (CR-IM). The aim of this study was to present our data regarding 
the utilization of RFA in the treatment of metaplastic and dysplastic BE. The basic 
goal was to evaluate the role of post RFA treatment in the term of BE recurrence 
prevention. We also evaluated morphologic structure of neosquamous epithelium 
(NSE) obtained from biopsy samples and processed on electron microscopy. 
The data indicated that in patients with long segment BE and hiatal hernia>3 cm, 
post RFA Nissen fundoplication has better protective effect than medical 
treatment. The morphologic structure of NSE showed presence of dilated 
intercellular spaces, which were present in higher extent in those patients who 
were treated with medications. 
To conclude, RFA procedure is safe and effective in the treatment of patients with 
BE. In selected patients antireflux surgery may be offered as a standard treatment 
due to its protective nature over NSE. 
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Barrett-ov jednjak (BJ) predstavlja metaplaziju i nastaje kada se normalni 
skvamocelularni epitel jednjaka transformiše u cilindrični epitel koji sadrži 
peharaste ćelije. Radiofrekventna endoskopska ablacija (RFA) je relativno nova 
procedura čija je bezbednost i efikasnost već dokazana u kompletnoj eradikaciji 
Barrett-ovog jednjaka. Cilj ove studije bio je da se prikažu naši podaci u lečenju BJ 
radiofrekventnom ablacijom jednjaka, a osnovi cilj studije bio je da se proceni 
značaj primenjenog tretmana nakon RFA u smislu prevencije recidiva BJ. Takođe, 
učinjena je evaluacija morfološke strukture neoskvamoznog epitela na osnovu 
endoskopskih biopsija koje su obrađene i pregledane elektronskom 
mikroskopijom. 
Naši podaci su ukazali da bolesnici koji imaju duži segment BJ i hijatalnu herniju 
>3 cm imaju manji stepen recidiva ukoliko je laparoskopska Nissen-ova 
fundoplikacija načinjena nakon RFA u odnosu na one koji su dobijali 
medikamentoznu terapiju. Analiza morfološke strukture neoskvamoznog epitela 
ukazala je da u ovom epitelu postoje dilatirani međućelijski prostori , ali da su u 
manjoj meri izraženi kod bolesnika koji su nakon RFA operisani. 
U zaključku, RFA je sigurna i efikasna procedura u lečenju bolesnika sa BJ. U 
određenoj grupi bolesnika antirefluksna hirurgija ima prednost kao standardni 
tretman nakon uspešne ablacije u cilju prevecije recidiva oboljenja u odnosu na 
medikamentoznu terapiju. 
 
Ključne reči: Barrett-ov jednjak, radiofrekventna ablacija, Nissen-ova 
fundoplikacija, inhibitori protonske pumpe 
 




















































































When Norman Barrett wrote his paper in 1950 he couldn’t even imagine how often 
his name will be mentioned when talking about one of the most intriguing and 
unsolved clinical problems - Barrett’s Esophagus (BE). Although, he reported it as 
a congenitally short esophagus, it was a first description of what we now know 
refer to as “presence of metaplastic or dysplastic columnar epithelium on the 
esophagus”. 1 However, it was another great work by Allison and Johnston in 
1953, in which first actual recognition of columnar lined esophagus was made. 2 In 
late seventies of past century Barrett esophagus is being recognized as a 
precursor of esophageal adenocarcinoma (EAC), and since than, incidence of 
EAC has increased dramatically, thus becoming the fastest growing incidence of 
all solid cancers in Western world. 3 It was this widespread of EAC that draw 
attention to the Barrett’s esophagus, making it recognizable as a consequence of 
gastroesophageal reflux and a cause of carcinoma.  
Today we now that Barrett’s esophagus (BE) is result of long lasting 
gastroesophageal reflux (GER). Its nature is metaplasia, the process in which one 
adult cell replaces another, as a response to chronic tissue injury.4 The prolonged 
exposure to the pathological reflux may bring the changes in the esophageal 
squamocellular epithelium as well as the growth of the new metaplastic columnar 
epithelium. The columnar epithelium formed in this manner should be more 
resistant to the damage caused by pathologic GER. 
The most widely accepted definition in the medical community nowadays explains 
Barrett’s esophagus is a ‘metaplastic condition where the squamous esophageal 
epithelium is replaced by the columnar epithelium containing goblet cells’. 5 
Although this definition is accepted in majority of the countries globally, there are 
some of those who practice slightly different definition. For example in Japan and 
Great Britain every macroscopically visible epithelium, columnar in its nature, 
which extents more than 1 cm above the level of gastroesophageal junction is 
being considered as BE.6 This standpoint may be more justified since it diminishes 
the probability of error, derived from the physician’s personal experience and the 
quality of the biopsy sampling. However, the American Gastroenterological 
Association in 2011 made a clear statement, that the presence of goblet cells in 
columnar epithelium is essential for the diagnosis of BE. This standpoint is 
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explained by general opinion that only metaplastic epithelium containing goblet 
cells predisposes to adenocarcinoma. Opposed to this, several publications 
proved that adenocarcinoma of the esophagus can develop from columnar 
mucosa, which does not contain goblet cells. 7  These studies derived the 
conclusion that glandular mucosa on esophagus caries similar cancer risk as 
specialized intestinal metaplasia. It was also shown that DNA of glandular mucosa 
on tubular esophagus, which does not contain goblet cells, is similar to the one 
which does, and that this DNA profile is the one that caries risk for neoplastic 
progression.8 
The dilemma about the BE definition is not the only one surrounding this clinical 
issue. The true incidence of BE, pathogenesis, surveillance and treatment issues 
are jet to be studied closely and standardized. Meanwhile, the emergence of 
HALO radiofrequency ablation for the treatment of metaplasitic and dysplastic BE 
has brought a new shift of the paradigm when it comes to BE management. 9 This 
study will address the efficacy of HALO RFA in the treatment of BE with the 
special emphasis on the post RFA treatment strategies.  
 
1.2. Epidemiology of Barrett’s Esophagus 
 
The true incidence and prevalence of Barrett’s esophagus remains unknown. This 
can be explained with the “quiet” symptomatology that BE caries and lack of 
objective data and large epidemiologic studies which would focus on detection of 
BE. These studies however, should cover broad population undergoing screening 
endoscopies, which makes them difficult to be well designed and conducted. 
Differences among different parts of the world in the prevalence of GERD, which is 
the major determinant of BE basis, make it more difficult for investigators to 
accurately determine its global prevalence. 
Several epidemiologic studies, based on the national surveys, can give us data 
from which we can make further assumptions and draw an estimated prevalence 
of population affected with BE. Swedish epidemiologic study covered a random 
sample population, and 1000 participants in whom upper GI endoscopies were 
performed. The specialized intestinal metaplasia was proven in 16 participants (5 
with long segment BE, 11 with short segment), with the conclusion that BE was 
found in 1.6% of general population in Sweden. 10 In the US based endoscopic 
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survey, 961 participants underwent upper GI endoscopy, during the scheduled 
colonoscopy. This study showed an overall prevalence of BE to be 6.8%, with 
majority of those found to have short segment BE. 11 Similar prevalence of BE in 
general population was found (5.6%) when simulation model was used by the US 
authors using the national data base. 12 
During the last two decades there has been a growing number of publications 
dealing with risk factors for the development of BE and EAC. Based on the current 
knowledge we can emphasize several factors that have been proven to contribute 
to the BE development. 
- Demographic factors: White race, male sex (male to female ratio 2:1), and 
older age (>50 years) are risk factors for the development of BE and EAC. 
Male sex and white race contribute BE progression to EAC. 13 
- GERD: Gastroesophageal reflux disease is a well-known risk factor for both 
BE and EAC. It is estimated that around 12% of patients with diagnosed 
GERD will develop BE. The risk of BE development and further progression 
to EAC is also dependent on GERD symptom duration and intensity. 14 
- Smoking: There are strong evidences that smoking is associated with an 
increased risk for the BE and EAC. This factor has been proven to be dose-
related and duration-related. 
- Obesity: Obesity (but not BMI) is a strong risk factor for BE development. It 
appears that there is special role of visceral adiposity in BE and subsequent 
EAC development. There are two mechanisms behind pro-oncogenic role 
of visceral adiposity. First is increased intraabdominal and intragastric 
pressure, which correlates with the intensity of GERD, and the second is 
activation of metabolic syndrome.15 
- There are evidences that Helicobacter pylori infection, and regular intake of 





The basic process behind etiology of Barrett’s esophagus is metaplasia. 
Metaplasia typically arises after prolonged tissue stress, or in response to 
abnormal tissue stimulation. 4 The nature of metaplastic epithelium should be 
defensive, meaning that this type of epithelium is more resistant to continuous 
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pathologic exposure. In the case of BE this prolonged tissue stress and stimulation 
is a consequence of chronic exposure of distal esophagus to gastric and duodenal 
contents. Patients with BE usually have defective function of lower esophageal 
sphincter (LES), resulting in unobstructed flow of gastric juice toward tubular 
esophagus. Among patients with GERD, those with BE are more often presented 
with low values of LES basal pressure, ineffective esophageal motility and 
completely displaced gastroesophageal junction (GEJ) due to hiatal hernia. These 
factors also contribute to the length of BE. It has been documented that patients 
with long segment BE have lower median values of LES basal pressure than those 
with short segment BE.16 
The process of BE formation can be divided in two phases. The first step is 
probably development of the so-called cardiac mucosa, a simple columnar 
epithelium, which does not contain goblet cells, nor does it secret acid or pepsin. 
This concept, although not universally accepted suggest that cardiac mucosa is an 
acquired condition which develops as a consequence of reflux exposure.17 As the 
reflux disease progresses, LES gradually losses its function, and the reflux 
episodes become more frequent and longer. This process may lead to the 
increase of the cardiac mucosa length. The second phase in the development of 
BE would be intestinalization of cardiac mucosa trough the development of goblet 
cells. The BE mucosa is called intestinal because all of the main mucosal intestinal 
cell types may develop inside this specialized epithelium. These are goblet cells, 
Paneth cells, enteroendocrine cells and enterocytes. 18 
The composition of refluxed content is one of the predisposing factors in the 
development of BE. In the first phase, which is the development of cardiac 
mucosa, there is probably a crucial role for acid reflux. Not only refluxed gastric 
acid but bile salts as well, have the decisive part in the process of intestinalization. 
There are two different suggested models how bile salts can contribute to BE 
formation. At the pH level 3-6 bile salts are soluble and non-ionized, and they 
affect cell junctions by exhibiting detergent like action. But what is more important 
in the pathogenesis of BE, bile salts may act as signaling molecules. It has been 
shown that in vitro culture of squamous cell epithelium (SCE) bile salts promote 
loss of differentiation of SCE. It is suggested that this activity is being conducted 
by activation of epidermal growth factor and down-stream of Akt and ERK1/2. 
There is a strong activity inside the injured epithelium towards damage repair, the 
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process which may end up in development of BE. 19 
Jet, another controversy is present in the pathogenesis of BE and that is the cell 
origin of BE. There are several hypotheses so far, but there are not enough 
evidences for none of those to be rejected or generally accepted. A recent 
hypothesis was that BE develop when cells from the level of the esophagogastric 
junction migrate upwards. This theory can explain the presence of fundic or gastric 
type columnar epithelium on tubular esophagus. 20 However, it can not explain the 
development of BE after esophagectomy and gastroplasty, in which case the GEJ 
region is resected. There is also a theory that BE develop from residual 
embriogenic type columnar cells, which rests there after the embriogenic 
development of esophagus and which are also located on the level of GEJ.21 
During the embriogenic development of esophagus these cells are being gradually 
“pushed down” by squamous cells. Another explanation of BE origin is that 
damaged matured SCE is going through the process of conversion to different 
epithelium type, a so called “transdifferentiation”.22 It is suggested that epithelial 
stem cells which are responsible for continuous reloading of SCE, under the reflux 
induced damage start to differentiate towards the columnar cell type. 23 The origin 
of these stem cells could be inside the basal layer of SCE or in the sub-mucosal 
esophageal glands. There is also a possibility that BE can derive from bone 
marrow progenitor circulating cells drawn there by chronic inflammation and strong 
molecular activity for mucosal repair as it has been shown in the rat model of 
reflux esophagitis.24 
There is a hypothesis that there can be even more that one origin of BE cells, and 
that further progression of BE is determined by the origin cell type from which BE 
has developed.  
 
1.4. Diagnosis and Classification 
 
The diagnosis of Barrett’s esophagus requires endoscopic visualization of 
columnar epithelium above the level of gastroesophageal junction lining the 
tubular esophagus, and esophageal biopsy histological confirmation of intestinal 
metaplasia. The physician performing upper GI endoscopy must evaluate several 
important landmarks, essential for the diagnosis and proper classification of BE. 
The gastroesophageal junction is verified as the top of the gastric folds. If the 
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metaplastic mucosa is present, it is identified as a “salmon” or pink colored with a 
rough surface, as opposed to squamocellular epithelium, which is pale gray and 
smooth. The squamocolumnar junction (SCJ) is than verified, and it is usually 
displaced proximally, and most often irregular due to the “tongues” of metaplastic 
epithelium extending upwards. 25 The sensitivity of white-light endoscopy alone for 
the detection and diagnosis of BE ranges from 80% to 90%. Novel endoscopes 
facilitates the imaging by employing several new technologies, such as 
chromoendoscopy, different magnification techniques, and confocal endoscopy, all 
of which contribute significantly to proper diagnosis of BE. These techniques also 
enables enchased visualization of suspicious dysplastic lesions inside BE. 26 
Traditional classification of BE as the long (>3cm) and short segment BE (≤3cm) 
still has its place in everyday clinical practice. It has been shown that patients with 
long segment BE have higher risk of progression to dysplasia and EAC. What 
remains more difficult for endoscopist is the identification of short segment BE. 
Again, this is where anatomical landmarks must be identified correctly, especially 
the top of the gastric folds. The identification of submucosal palisade vessels zone 
may be helpful, as these vessels are present on tubular esophagus, while 
columnar epithelium covering those could be with great certainty proclaimed as 
metaplastic and must be sampled for histologic evaluation. 27 
A traditional short and long segment grading segment is replaced with more 
standardized and validated grading protocol, the Prague C&M classification of BE. 
The C stands for circumferential extent of columnar epithelium in centimeters, and 
M for maximal extent of columnar epithelium in tubular esophagus. Again, the 
most important landmark is the top of the gastric folds, which must be properly 
determined as the measurement of C and M starts from that point. Several studies 
have validated the application of Prague C and M criteria on the expert level, 
where it has proved to have high interobserver agreement, but it has also gain 
wide acceptance and was validated in real time endoscopy and community 
hospitals.28 
The histologic examination is based on esophageal biopsy sampling. The 
technique and principle of biopsy is extremely important. That is why standardized 
biopsy protocol was created (The Seattle Protocol). This protocol consists of four 
quadrant jumbo forceps biopsies on every 1 cm of BE with separate biopsies of 
eventual mucosal abnormalities. This rigorous protocol has been put to question 
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when Kariv et al proved that it does not more reliably predict the detection of 
cancer in patients with high grade dysplasia, than less invasive biopsy protocols. 29 
Still, the following of defined protocol enables more trusting primary diagnosis and 
therefore a possibility od adequate surveillance or treatment. Method of taking the 
biopsy sample should be standardized as well. Experts recommend usage of 
“jumbo” forceps and a specific technique. Stomach must be desuflated during 
evaluation of GEJ, because overinsuflation can flatten the gastric folds. Than, the 
biopsy forceps jaws must be perpendicular to the surface of the tubular 
esophagus, and the suction must be applied to bring the esophageal mucosa as 
close as it can get to the top of the endoscope. This technique is being called “turn 
and suction” 
The spectrum of histological findings inside BE is by convention divided into four 
basic groups. 30, 31 
1. Columnar epithelium containing no dysplasia 
- There are three distinct types of non-dysplastic columnar epithelium in 
the BE setting. Those are: gastric fundic type or oxintocardiac mucosa 
(containing glands, absence of goblet cells), cardiac type (columnar 
epithelium which contain no glands, and has marked inflammatory 
activity) and intestinal metaplasia (columnar epithelium which contain 
goblet cells). Only the later of three is proven to have malignant potential, 
and is being consider as the only histology type by AGA and American 
College of Gastroenterology (ACG) that can be proclaimed as Barrett’s 
esophagus. Two different subtypes of intestinal metaplasia (IM) can be 
identified, “complete and incomplete IM”. Incomplete IM have is unstable 
epithelium with higher risk of progression towards dysplasia and EAC. 
2. Indefinite for dysplasia 
- This histologic type is utilized when there is uncertainty whether the 
epithelial changes are caused by cellular atipia or substantial 
inflammation. What characterizes this histologic category is a surface 
maturation, but the presence of irregular nuclei inside the deep glands. 
3. Low grade dysplasia (LGD) 
- The crucial histologic finding in this BE subtype is cellular atipia which 




4. High grade dysplasia (HGD) 
- Histological findings inside HGD show both cytologic and architectural 
abnormalities including loss of nucleus polarity, possible presence of 
atypical mitoses and glandular distortion. Practically, HGD can be 
consider as carcinoma in situ, with malignant cells that do not invade 
lamina propria.  
 
1.5. Natural Evolution of Barrett’s Esophagus 
 
When we use the term “natural evolution” of Barrett’s esophagus we usually think 
about the progression from BE intestinal metaplasia to dysplasia and esophageal 
adenocarcinoma. It is estimated that patients with BE have 35- 125 times more 
chance to develop EAC than those without BE. Still, the great majority of people 
diagnosed with BE will never develop EAC.  
Patients with BE intestinal metaplasia without dysplasia have low risk for 
developing EAC. A great number of studies had this issue examined over the past 
years. Well-designed and contemporary studies have shown that risk of 
progression from IM to EAC range from 0.12% to 0.43% per year. If we include 
high-grade dysplasia with EAC as a final endpoint of progression the risk rises to 
approximately 0.23- 0.63% per year. 32 Among those with non-dysplastic BE there 
is higher risk towards progression to EAC for patients with long segment BE. It is 
estimated that risk for progression increases significantly with every cm of BE 
length. 33 These data are not in concordance with previous studies, which showed 
that risk of progression for BE IM approximately 0.5%. These were the data from 
often-cited meta-analysis conducted by Shaheen at al., which took into account 25 
articles dated from 1984 untill 1998. 34 What makes this study less objective for 
general population is that volume of the studies included in the meta-analysis 
directly influenced the results, in the manner that smaller studies reported higher 
risk of progression. The nationwide cohort study in Denmark conducted by Hvid 
Jansen et al reported however very low risk of annual progression to EAC among 
BE patients, which was shown to be 0.12%, and 0.26% if HGD was taken into 
account. 35 This study pointed that patients with IM BE have 11 times more chance 
of developing EAC compared to general population. 
The risk of developing malignancy rises for those BE patients who develop low-
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grade or high-grade dysplasia. A study by Reid and colleagues showed that 4% 
patients with BE LGD progress to EAC in a 5-year period, and that 61% of those 
with BE HGD would develop EAC in a 5-year period. 36 The differences were 
showed among patients regarding the speed of progression, where some patients 
have stable disease over time before rapidly progressing to EAC, while others 
progress slowly in steady pace. 37 
There are some issues that must be taken into consideration when we analyze the 
novel data concerning the rate of progression of non dysplastic BE to EAC and its 
role when deciding about conduction of the surveillance and treatment in this 
subset of patients. For example, for patients with non-dysplastic BE the leading 
gastroenterological associations worldwide do not recommend endoscopic 
treatment of BE, but rather advise different surveillance protocols. 5, 38 Still, ASGA 
guidelines recommend endoscopic radiofrequency ablation treatment of BE for 
patients with proven HGD, LGD, but also for selected cases on non dysplastic BE. 
39 This is the reason why a physician must take into account the risk factors for 
progression such as duration of reflux symptoms, hiatal hernia size, length of BE 
segment, gender, ethnicity, obesity and others when considering the general risk 
of progression towards EAC.40  
In an interesting paper, which was set to introduce the case for non-dysplastic, BE 
ablation, authors address several very important issues. 41 The first is that BE risk 
of progression towards EAC is artificially underestimated because of the current 
tendency not to count the patients with prevalent cancer and HGD occurring one 
year from diagnosis and the second is the problem of BE overdiagnosing that also 
contribute to decrease of the progression risk. Therefore, when assessing an 
individual patient, the natural evolution of BE towards EAC cannot be estimated 
only from cohort studies, but all the other aforementioned risk factors must be 
taken into consideration as well.  
 
1.6. Barrett’s Esophagus Management 
 
There is a great deal of disagreements in contemporary literature regarding the 
management of BE. Above all, these issues reflect our inability to predict which 
patients will progress towards EAC, and to standardize our approach. Still, several 
management strategies are proposed, basically consisting of surveillance and 
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Ever since the recognition of potential malignant transformation of BE towards 
EAC took place, screening and surveillance of potentially risky patients has been a 
mainstay strategy in management of Barrett esophagus. The rationale for this 
approach lies in the possibility to identify patients with GERD who have a higher 
chance of developing BE, to follow the BE patients’ condition with a final goal to 
pinpoint the moment of dysplastic transformation or early neoplasia, and then to 
perform the necessary treatment. 
The process of identifying those at risk among the GERD patients should include 
some of the following factors: duration of GERD symptoms, presence of hiatal 
hernia, age 50 or older, male sex, obesity, white race, tobacco use etc. Once 
identified, and histologically proven, BE patients are submitted to different 
surveillance protocols which differ in details among associations and their 
guidelines. 5, 38 Basically, for non-dysplastic BE, surveillance consists of regular 
endoscopic follow-up on every 3 to 5 years. It is recommended that endoscopic 
evaluation is performed with white light endoscopy. The specific biopsy protocol 
should also be utilized, consisting of four quadrant biopsies taken on every 2 cm of 
metaplastic epithelium, and separate biopsies should be taken from any mucosal 
abnormalities. Once established low-grade dysplasia, independent pathologist 
should confirm it. After verification of LGD, those patients should undergo 
endoscopic surveillance on every 6 to 12 months, again depending on different 
guidelines. The biopsy protocol should consist of taking four quadrant biopsies at 
every 1 cm of BE epithelium, and endoscopic mucosal resection of mucosal 
irregularities, such as lesions elevated from the level of surrounding mucosa. 38 At 
the time high-grade dysplasia is being recognized and confirmed, endoscopic 
surveillance should take place on every 3 months, unless some kind of eradication 
treatment is being employed. Different biologic markers are being introduced into 
studies and even clinical practice, but up to this moment none of the individual 
markers or panel of markers have shown efficacy in identifying those in higher risk 
for progression towards carcinoma. 42 So, none of those can be recommend in 
routine clinical practice, although the quest for identifying “the holy grail” among 
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the different biological markers which will be able to stratify patients in risk, 
remains the mainstay of different studies in the field of BE carcinogenesis. 
If the end point of surveillance is to prevent EAC or to identify the early neoplastic 
changes, than the current surveillance protocols might be highly ineffective. There 
are several reasons for that. First of all, when identifying patients in risk for 
developing BE, clinicians starts from recognition of those having GERD symptoms. 
It is however well known that majority of patients with short-segment BE does not 
experience or does not report GERD symptoms. 43 Second important data is that 
approximately 40% of patients diagnosed with EAC have no prior history of GERD, 
and that less than 10% of those diagnosed with EAC was previously diagnosed 
with BE. 44 There are no clear literature evidences, that endoscopic screening and 
surveillance can reduce mortality from esophageal adenocarcinoma. 
 
1.6.2. Medical Treatment of Barrett’s Esophagus 
 
Proton pump inhibitors (PPIs) are currently most efficient and most prescribed 
medications in the treatment of GERD. The PPIs are extremely potent in relieving 
the GERD symptoms as in the treatment of GERD complications e.g. erosive 
esophagitis. Their role in the maintenance therapy of patients with BE have also 
been proved. It has ben shown repeatedly that long term PPI therapy can slow the 
progression of BE metaplasia towards dysplasia and carcinoma. This specific 
effect of PPI medications can be achieved with substantial decrease in 
esophageal acid exposure, leading to reduction of inflammatory changes, such as 
promotion of mucosal healing and decrease of cell proliferation. 45 Therefore it 
seems reasonably to employ PPIs in the maintenance treatment of BE patients. A 
study conducted by Kastelein et al. showed that BE patients who underwent PPI 
therapy had decreased risk of neoplastic progression opposed to those taking 
histamine-2 receptor antagonists. 46 This was the Dutch cohort study, covering 540 
patients, with a median follow-up of 5.2 years. It has been calculated that the risk 
of neoplastic progression for BE patients regularly taking PPI medications is 
decreased by 75%. Above all, it has showed that regular PPI therapy can even 
lead to regression of intestinal metaplasia, being observed on endoscopy as 
decrease of BE length and occurrence of squamous epithelium islets inside the BE 
epithelium. These studies however included small study population and the 
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evidences shown were strongly affected by inter-observer variation. A large meta-
analysis was conducted with the intent to establish the potential role of PPIs in 
decreasing the risk of BE neoplastic progression. 47  The study included 2813 
patients and 317 cases of EAC and BE associated HGD. The end-point of the 
study was that chronic intake of PPIs was associated with 71% decreased risk 
from neoplastic progression towards EAC and HGD. Opposed to this, a large 
case-control study by Hvid-Jansen and colleagues covered the population of 9883 
patients with newly diagnosed BE. Median follow-up in this study was 10.2 years, 
during which 120 cases of EAC and HGD were confirmed. The relative risk for 
progression to HGD and EAC was higher in those patients who had lower 
compliance to PPI intake, than in those who took PPIs regularly. 48  
Although PPI treatment will improve symptoms and heal reflux esophagitis in 
majority of GERD patients, and also as mentioned before will decrease risk of 
neoplastic progression among BE patients, it will not affect the number of reflux 
episodes, but only change the acidity of refluxed content. This fact is extremely 
important in BE patients’ treatment, considering the fact that bile salts have a 
special role in BE initiation and progression. It is somehow alarming that dramatic 
increase of EAC incidence, started when PPIs were introduced, in 1980s. 
Therefore, it has been hypnotized that PPI medications could change the natural 
course of GERD, shifting its spectrum of complications, from erosive disease and 
peptic stricture towards Barrett esophagus. 49  There is a rational explanation 
behind this. Chronic usage of PPIs elevates the average pH value in distal 
esophagus to >4 in a great majority of time over the 24h period. This is the pH 
value where bile salts may exhibit their potentially pathogenic role by affecting the 
cell junctions, and acting as signaling molecules. An experimental study on rats 
proved that gastric acid suppression with PPIs in the presence of duodenal reflux 
was associated with increased rates of intestinal metaplasia and molecular 
proliferative activity. A study employing sucrose permeability test in patients with 
BE showed that PPI intake was related with the higher degree of paracellular leak 
inside BE mucosa, whereas BE length did not make any statistical difference in 
the degree of leak.50 This could implicate higher permeability of BE mucosa for the 
bile salts molecules in the pH>4 medium.  
As a conclusion, although there are clinical evidence that could implicate beneficial 
role of PPIs in the treatment of BE, a novel studies evidences show a great deal of 
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concern for implementation of long term medical treatment for patients with BE. 
 
1.6.3. Barrett’s Esophagus and Antireflux Surgery 
 
Among patients with GERD, those with BE are presented with higher incidence of 
LES dysfunction and ineffective esophageal motility, larger hiatal hernias, and 
more frequent and aggressive gastroesophageal reflux measured by 24 hour pH/ 
impedance testing. That is why those patients represent a special challenge to 
treat, both with intent to eliminate the GERD symptoms and stop the further 
alterations inside BE mucosa. Adequately preformed, antireflux surgery (ARS) can 
achieve both aforementioned goals. Utilization of ARS for patients with BE is 
getting a stronger role, when one knows that behind BE initiation and further 
progression is weakly acid and alkaline reflux, that cannot be stopped with medical 
therapy alone. 
The positive impact of ARS on BE can be obtained in three modalities. The first is 
regression or lost of intestinal metaplasia, second is loss of dysplasia, or its 
regression to IM, and the third is induction of BE “quiescence”, by which the 
possibility of further progression is being diminished.51 
An often-cited study by Gurski et al followed 91 patients with BE IM and LGD out 
of which 77 patients underwent laparoscopic Nissen fundoplication (LNF). The 
criteria for regression were histologic confirmation of regression on two 
consecutive biopsies, 6 months apart, and all subsequent biopsies confirmation of 
IM or LGD loss. The histologic regression in ARS group was noted in 36.4% of 
patients, where 68% of LGD showed histologic signs of regression. The rate of 
regression was strongly dependent on BE length and time after surgery.52  
A study by Cendes et al also highlighted the role of antireflux surgery in patients 
with short segment BE. In this study three different antireflux surgery types were 
evaluated, including duodenal switch, duodenal diversion combined with acid 
suppression and laparoscopic Nissen fundoplication (LNF). The study revealed 
high success rate in eradication of intestinal metaplasia, with overall success rate 
ranging from 60 – 65%. None of the surgical procedures employed showed 
superiority over the other two, so the authors concluded that LNF should be 
employed as the procedure of choice for patients with SSBE, as it was less 
invasive, and equally effective.53 
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The role of antireflux surgery in possible prevention of EAC was also evaluated. In 
the study, which evaluated 239 previously randomized patients, the late effects of 
medical therapy and ARS were assessed. 54  The study found no statistical 
differences between ARS and conservative treatment with PPI’s in the term of late 
EAC incidence. The annual rate of progression towards EAC in this study 
population was 0.4%. The authors concluded that antireflux surgery could not be 
advised to patients with complicated GERD with the expectation of definitive relief 
from antisecretory drugs, nor could it be recommended as a protection against the 
EAC. A study by Lagergren et al also evaluated the effect of ARS on potential BE 
progression towards EAC. 55 The study population consisted of 218 cases of EAC 
and 820 controls. Among those diagnosed with EAC, 7 patients (3.7%) had 
undergone previous ARS. The study revealed that 4 of those 7 patients had used 
antireflux medications continuously. Hence, the authors postulated that occurrence 
of EAC after antireflux surgery may be due to the persistent reflux after ARS, 
meaning that fundoplication either disrupted in time or being inadequate at the first 
place. The systematic review of Chang et al dealt with the issue of potential 
protective role of antireflux surgery and medical therapy. The authors showed that 
the probability of progression in patients with antireflux surgery is 2.9%, and for 
those with medical therapy 6.8%. The authors found a statistically significant 
advantage of antireflux surgery over medical therapy with regard to the probability 
for BE regression.56 
Along aforementioned studies, which have indicated that BE can regress after 
ARS in histological sense, there were also studies that highlighted the molecular 
changes in BE mucosa after antireflux surgery. Those studies showed reduced 
expression of p53 and COX1 after successful antireflux surgery. 57  The later 
finding may address to the quiescence inside BE epithelium, the one of proposed 
mechanisms of protective antireflux surgery role. 
 
1.6.4. Endoscopic treatment 
 
Despite several aforementioned modalities of BE surveillance, and reflux 
treatment with medications and ARS, the need for direct intervention and complete 
removal of BE epithelium persists among physicians. The complete eradication of 
BE mucosa is achievable, and effective with several endoscopic techniques. 
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Basically, all of those can be divided into two groups: 
 
a) Endoscopic ablative techniques 
b) Endoscopic mucosal resection  
 
The aspects of all of these specific methods will be presented in the following text. 
However, in the quest for ideal endoscopic method for the eradication of BE, one 
must consider this procedure to be safe, effective and easily reproducible. It has 
been stated that ideal endoscopic procedure for BE eradication should have next 
attributes. Firstly, of all it needs to be feasible enough to be performed by any 
endoscopist skilled in interventional endoscopy. Secondly, the procedure must set 
the goal to eradicate BE completely. Thirdly, the endoscopic method must be safe, 
with minimal rate of procedure related complications, such as perforation, bleeding 
and stricture formation. At the end it must be well tolerated by patient, and of 
course if possible, it should be performed on the ambulatory one-day basis.58 
There are several endoscopic methods used for BE mucosa eradication based on 
the principle of mucosal ablation. The ablation of the metaplasic or dysplastic 
epithelium is achieved by induction of the necrosis in the superficial mucosal 
layers. The optimal procedure should, however do minimal damage to deeper 
layers of esophageal wall, therefore minimizing the possibility of the potential 
complications. The usage of different ablative endoscopic techniques such as 
photodynamic therapy, laser ablation method, argon plasma coagulation, 
multipolar electrocoagulation, cryotherapy and radiofrequency ablation, has been 
presented in medical literature. 
Photodynamic therapy (PDT) of BE is based on combination of systemic 
application of photosensitizer followed by endoscopic delivery of laser light energy 
over the whole surface of BE mucosa. The photosensitizer substance most often 
used is Porfimer sodium, which is usually being systemically injected 24 hour 
before the delivery of light energy. This substance is FDA approved in the USA for 
destruction of esophageal pre-neoplastic or early neoplastic lesions in the subset 
of patients who do not undergo esophagectomy. 59 In the study conducted by 
Faroulis it has been shown that PDT was highly effective in the treatment of HGD 
and intramucosal carcinoma with complete response rate around 80% at the 14 
months follow-up. The most often occurred complications described in this study 
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where erosive esophagitis, photosensitivity and stricture of the esophagus 
requiring dilatation in 6% of patients. Overholt et al conducted randomized clinical 
trial for patients with HGD in which one group of patients was treated with PDT 
and omeprazole, while other group of patients received omeprazole treatment 
only. The early effects of study shown that PDT was more effective than 
omeprazole treatment only, in the term of lowering the risk towards EAC 
progression, whit 13% of patients receiving PDT and omeprazole together, and 
28% of those submitted to omeprazole alone progressed to EAC, respectively. 
Study showed that PDT treatment was burdened with high rates of procedure 
related complications such as photosensitivity in 69% of patients and esophageal 
stricture in 36% of them. 60 Five years results of the same study revealed that 77% 
of patients who had underwent PDT therapy remained HGD free versus only 39% 
of those who had received omeprazole alone.61 PDT has been proven method in 
the treatment of HGD, with satisfactory long term results, but obviously with high 
rates of complications, making this procedure not recommendable for broader 
population than those with HGD of intramucosal carcinoma, not suitable for 
esophagectomy. 
Argon plasma coagulation (APC) is another ablative technique in use for complete 
eradication of metaplastic and dysplastic Barrett esophagus. It is a system, which 
delivers argon gas with trough the scope catheter. The gas is than exposed to 
monopolar electrode, resulting in dispersing heated gas stream, which is applied, 
on diseased mucosa. In the study showing late results of two randomized trials, 
the effects of APC treatment where better than surveillance only, in the term of 
reduced risk for BE progression. The studies were carried out on patients with 
non-dysplastic BE and LGD. One patient in APC group progressed towards HGD, 
versus three in surveillance group.62 It has been reported that ideal candidates for 
APC treatment are patients with short segment BE and good control of 
gastresophageal reflux. This study reported relatively high incidence of 
subsquamous IM after APC treatment. 63 Factors contributing to recurrence of IM 
or subsquamous BE in this study were long segment BE and decreased dose of 
PPI medications. There is substantial amount of BE recurrence following the 
successful APC treatment of BE. This was noted in up to 66% of patients in a 15 
months follow-up. 64 
There are no comprehensive literature reports showing utilization of laser 
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coagulation, cryotherpay and multipolar coagulation in ablative endoscopic 
treatment of Barrett esophagus.  
The most applicable and worldwide exploited endoscopic ablation procedure is 
radiofrequency ablation with HALO system. This procedure will be presented and 
discussed in details in the following chapter.  
Endoscopic mucosal resection (EMR) technique is a procedure used for staging 
and treatment of BE metaplasia and dysplasia. There are several different ways to 
carry out this procedure, including usage of submucosal injection followed with 
utilization of monofilament snare, cap or band ligation system. The basic 
advantage of the EMR technique over every ablation procedure is that it provides 
an adequate sample for accurate histologic staging. The biopsy sample obtained 
by EMR is usually 15- 20 mm in diameter, and sufficient enough to asses the 
resection margins. Therefore, it may be use either as therapeutic weapon, or a 
bridge towards more radical options, such as esophagectomy. 
Its application is practically warranted in all cases of BE metaplasia or dysplasia 
presenting as nodal lesions. However, the limitation of the procedure is a surface 
area that can be treated, due to the high risk of postprocedural esophageal 
strictures. Even after successful mucosal resection of nodal lesions, the 
surrounding mucosa still carries the risk of neoplastic progression and therefore 
must be treated. That is the reason why currently we have numerous studies that 
finds combination of EMR and ablative techniques as a gold standard in the 
endoscopic treatment of BE with HGD. 
A recently published study proved this standpoint. Smith et al evaluated 27 EMR 
specimens obtained from 21 patients underwent EMR for early EAC. The basic 
intent of the study was to evaluate presence of IM in those specimens. Although 
IM was not found in 10 out of 27 specimens, further analysis showed that in 3 of 
those it was present in previous EMR specimen, in 4 in previous biopsy 
specimens, and in 2 more in esophagectomy specimen following radical surgery. 
The authors concluded that IM is necessary predictor of EAC; therefore 
surrounding mucosa must be eradicated after successful EMR procedure.65 
British authors presented their experience in combined HALO RFA and EMR 
endoscopic treatment of BE related HGD and intramucosal carcinoma (IMC). The 
study covered the 6-year period, ending in 2013, and included 500 patients from 
UK registry.66 It has been shown that complete eradication or dysplasia and IM 
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rates improved over time, as evaluated in the second study period (2011- 2013). 
However, the risk of progression towards EAC remained 2- 4% over the whole 
study period, despite technical advances and higher success rate in eliminating 
the HGD.  
Chadwick et al have made the comparison between effectiveness of EMR and 
RFA methods in the systematic literature review. The authors found similar 
eradication rates of dysplasia between two methods, although the majority studies 
included in the literature were single center experience, and only one made direct 
comparison between two techniques. Both methods proved to be highly efficient 
on a median follow-up of 23 months, with complete eradication of dysplasia being 
present on 95% and 94%, for EMR and RFA respectively. However, EMR studies 
revealed much higher rate of procedure related complications, such as 
esophageal stricture, which was present in 38% of EMR treated patients versus 
4% of RFA patients.67 
To conclude, EMR remains superior endoscopic treatment method for dysplastic 
nodular BE lesions in well-staged patients. The procedure must be accompanied 
with ablative technique, preferably RFA. This combined approach should 
guarantee superior treatment outcome, and minimize high rate of strictures 
resulting from EMR of broad field Barrett’s mucosa. 
	
1.7. HALO Radiofrequency Ablation of Barrett’s Esophagus 
 
You can hardly encounter more excitement about any new technology in the field 
of esophagology than the one following the introduction of the HALO 
radiofrequency ablation for the Barrett’s esophagus. Surgeons and 
gastroenterologists dealing with this pathology gain strong, effective and safe 
weapon against the precancerous lesion, and made a lot of guidelines shifting in 
the BE management. With the number of HALO RFA procedures growing each 
day worldwide, issues emerge concerning its indications, durability and true 
effectiveness in the cancer prevention. 
 
1.7.1. The Procedure Overview 
 
HALO ablation system (Covidien, Sunnyvale, CA, USA) is based on 
radiofrequency energy which is delivered over the BE mucosa through the 
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catheters for circumferential (HALO 360) or focal ablation (HALO 90). 68 The 
principle behind this method is to deploy high power energy of approximately 
300W, over the extremely short period of time (<300ms). The depth of the ablation 
is strictly defined, and if the procedure is followed there is a minimum risk of 
injuring the deeper esophageal layers. Approximately, depth of ablation is around 
700µm, reaching to lamina muscularis of mucosa, but without extension towards 
submucosal. The electrode spacing is extremely narrow, less than 250µm, making 
the energy deployment even more superficial. 
Besides regular flexible endoscope for upper GI endoscopy, the equipment for 
HALO RFA should contain the following: HALO energy generator, HALO 360 
sizing balloons, HALO 360 balloons for energy deployment (various sizes ranging 
from 18 to 31 mm in diameter) or over the scope mounted catheter for focal 
ablation HALO 90.  
Generally, HALO 360 system should be used for longer, circumferential segments 
of BE. HALO 90 is designed for focal ablation of shorter BE segments, and for 
treatment of residual fields of BE mucosa after treatment with HALO 360. 
The process starts with inspection endoscopy and administration of 1% 
acetilcystein used for dissolution of mucus on esophageal wall. Getting the right 
landmarks for the measuring follows trough the course of procedure. Basic 
landmark is top of the gastric folds, and the chart for the procedure demand to 
write that landmark. The measuring of esophageal diameter starts 10 cm above 
that point. Before taking the endoscope out, the guidewire is introduced, and 
placed preferably through the pyloric channel. The HALO 360 sizing balloon is 
than open, calibrated and placed into the esophagus over the guidewire. The 
sizing is taking its course down the distal 10 cm of the esophagus, finish at the 
level previously set as the top of the gastric folds. After every measurement, one 
must write down the diameter of the esophageal lumen at that point, followed with 
the size of energy deployment catheter recommendation. The smallest 
recommended catheter should be utilized for the procedure. During one HALO 360 
session maximal extent of treated mucosa should not exceed 6 cm.  
After the measurement process, the ablation catheter is introduced over the 
guidewire, followed by endoscope. The balloon covers 3 cm, and after it is 
insufflated, and its position checked by endoscope, the energy deployment starts 
by pressing the pad connected to generator. The amount of energy deployed is 
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10J for metaplastic epithelium and 12J for dysplastic lesions. If the process of 
energy deployment was correct, it should be confirmed on the generator. The 
catheter is than placed 3 cm bellows the previous position, and the process is 
repeated. The overlapping of the two consecutive ablation fields should be 
minimal. The ablated mucosa is in form of white integument, which is being peeled 
down by endoscopic cap. After all of the mucosa was peeled down, the process of 
ablation is repeated over the whole area of treated mucosa. The characteristic 
appearance of well-ablated mucosa is in literature being described to be salmon 
colored.  
The HALO 90 procedure starts also with the endoscopic inspection, followed by 
1% acetilcystein washing of mucosal surface. The HALO 90 catheter is than 
mounted on the top of the endoscope in the manner that it resembles “baseball 
cap” on the monitor. Than the endoscope along with the catheter is being gently 
introduced into the esophagus, and care must be taken not to injure the 
pharyngeal area. The active electrode is than properly positioned, and afterwards 
deflected, therefore getting the optimal contact with the mucosal field, which is 
intended to treat. Two touches of the pad ensure that sufficient energy is 
deployed. Further, scraping of the treated mucosa is being performed with the 
electrode, after which the procedure is repeated, again until the salmon colored 
ablation filed appears. 
The procedure is being carried out under conscious sedation (HALO 90), or in 
general endotracheal anesthesia for HALO 360 procedure. Duration of procedure 
is approximately 15- 20 minutes for HALO 90, and 20- 25 minutes for HALO 360. 
The procedure is well tolerated by patients and majority of them should leave the 
hospital same day, meaning that it can be routinely practiced on a ambulatory one-
day basis. 
 
1.7.2. Treatment Outcomes  
 
One of the first studies performed during the development of HALO system was 
the one by Ganz et al. Authors applied HALO system on porcine model and on 
humans, planned for esophagectomy. The bottom line of this study was to precise 
the energy that needs to be delivered to achieve complete epithelial ablation, but 
without the injury of deeper esophageal layers. In this study energy levels from 8 
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to 12 J/cm2 proved to be sufficient in achieving the mucosal ablation of the tissue 
that came into the contact with the electrode. These levels of energy density 
provide the ablation till the level of lamina muscularis mucosa. This experimental 
study showed that if the higher density energy was applied (20 J/cm2), it has led to 
deeper submucosal injuries and subsequent stricture formation.69 
Ablation of Intestinal Metaplasia (AIM) I multicenter trial was launched, for the 
treatment of patients with non-dysplastic BE. The trial was initiated with the intent 
to establish the proper doze of energy that need to be deployed. As a part of the 
AIM I trial Sharma et al. reported that 8 J/cm was insufficient for the majority of the 
patients and that satisfactory complete response rates were obtained with the 
energy levels 10 and 12 J/cm2. 70 These results were followed by AIM-LGD trial 
were high success rates were showed in complete eradication of LGD and IM, 
100% and 60% respectively, on a 1 year follow-up. The energy level was set on 12 
J/cm2. 71 On the two-year follow-up all patients had complete eradication of LGD 
and all but one had complete eradication of IM.  
The studies, which followed, showed great results in complete eradication of BE 
dysplasia and IM, being over 90% in tertiary centers. For example, a study 
conducted by Fleischer et al presented that complete eradication of IM was 
achieved in 98% of patients on a 2.5 years follow-up.72 However, the procedure 
gain wide popularity, due to its safety profile, and we have various literature 
reports coming even from community centers. In one such report by Lyday et al 
429 patients were included from several community centers. The outcomes were 
highly satisfactory, without serious adverse effects, and low percentage of 
strictures (1.1%), where complete eradication of dysplasia was achieved in 89% of 
patients and IM in 72% on a median follow-up of 9 months. 73 This study could 
implicate high reproducibility of the procedure. 
But the study that opened up the door for broad acceptance of the HALO RFA 
procedure was the one which results were published in 2009.9 This was the 
multicenter randomized trial that included patients with non nodular, dysplastic BE, 
not longer than 8 cm. Patients were randomly assigned in 2:1 session to receive 
either HALO RFA treatment (up to 4 sessions) or an endoscopic sham procedure. 
The primary outcome variables were complete eradication of HGD, LGD and IM. 
The secondary study outcomes were to evaluate the rate of progression after 
RFA, and to establish whether the procedure can decrease the risk of neoplastic 
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progression. Overall, 127 patients underwent randomization, 84 receiving RFA 
treatment and 43 sham endoscopic procedure. Complete eradication of HGD was 
achieved in 81% of patients, and in 77.4% complete eradication of IM was 
achieved, significantly statistically higher than in sham control group. In the RFA 
group 3.6% of patients had disease progression in the course of the study, and the 
cancer incidence was 1.2%. The study showed that RFA treatment resulted high 
eradication rates of both dysplasia and IM, and reduced risk for disease 
progression. 
Currently, most of the leading gastroenterological associations recommend HALO 
RFA as a treatment of choice for patients with histologically proven HGD, LGD, but 
not for those with IM, or for only selected IM metaplasia patients. The reason for 
this opinion is that procedure cannot guaranty lower risk for further progression in 
IM BE patients, and that it is not cost effective opposed to regular surveillance 
protocols. However, in the clinical practice, all three histological types are being 
treated with HALO RFA procedure, on daily basis. There are several why IM BE 
should be treated with HALO RFA, and the details for this will be presented in 
discussion part. 
 
1.8. The Concept of Dilated Intercellular Spaces in GERD and Barrett 
Esophagus 
 
In the context of current study a dilated intercellular spaces (DIS) will be evaluated 
in two separate manners. Firstly, to enlighten the role of DIS in the pathogenesis 
of BE, and secondly to present the literature data regarding the presence of DIS in 
neosquamous epithelium (NSE), with a special emphasis on the post RFA 
treatment. 
The first time the dilated intercellular spaces were described in two independent 
papers was by Pope in 1978 and then by Hopwood in 1979. A paper published by 
Tobey et al. was the first to make a clear clinical connection between the DIS and 
gastroesophageal reflux disease, showing that the subject with erosive and non-
erosive GERD had similar morphologic findings and the measurements of 
intercellular spaces, as opposed to healthy controls.74 Therefore, DIS can be 
classified as microscopic feature of GERD. It has been postulated that DIS 
contribute to increased permeability of esophageal squamous cell epithelium 
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(SCE), and that heartburn will likely appear in the presence of DIS due to acid 
stimulation of the sensory nerves trough the frail epithelium. 49, 75 Once the H+ 
ions enter the highly permeable SCE, they led to sensory nerves stimulation and 
onset of heartburn or retrosternal pain. What also happens is that they induce the 
cell damage and in case of excessive long-term reflux, cell death. That is the 
mechanism behind the esophageal erosions formation.76 It has been previously 
shown in rabbit experimental model that bile acids may contribute to DIS formation 
both in acidic or weakly acid environment.77 In this study, bile acids in the acid 
solutions (pH 2), and weakly acid solutions (pH 5) lead to induction of increased 
permeability of esophageal mucosa and decreased transepithelial electrical 
resistance. Same study group conducted an investigation on 14 healthy 
volunteers, who were treated with infusion of acidic, weakly acidic, acid-bile and 
neutral infusions, administered 5 cm above the level of gastroesophageal junction. 
The biopsy specimens were taken after infusion treatment, and the presence of 
DIS was evaluated with electron microscopy. The study showed that both acid and 
weakly acid infusions provoked DIS without differences in the effect.78 A recent 
publication by Ghatak et al explains the possible mechanism of bile salts acting as 
main pathologic determinant in DIS induction. 79 The study was based on in vitro 
formed cell cultures obtained from human tissue biopsies. These cell cultures were 
treated for 6 days with bile salts cocktails at pH 7.4, pH 5 and control media as 
well. The transepithelial electrical resistance was measured in the cell culture, as 
well as EPC1 cell growth. The morphologic status of three major junction 
complexes such as desmosomes, adherence junctions and tight junctions status 
was also observed by transmission electron microscopy. It has been shown that 
exposure to bile salts at pH 5 decreases the epithelial barrier function, causes the 
loss of stratification of SCE and lead to disruption of major epithelial junctions. The 
pH 5 media on which bile salts proved these pathogenic abilities resemble the one 
in patients with GERD treated with proton pump inhibitors. The study implicates 
that this acting of bile salts may play role in pathogenesis of refractory GERD. 
Previous study of Gathak et al. proved that bile salts have signaling effect on 
damaged esophageal epithelium, leading to the loss of differentiation and possible 
transformation towards columnar epithelium.19 
So, what impact could bile salts and weakly acid reflux have on neosquamous 
epithelium (NSE), the one that develops after the successful RFA ablation? Jovov 
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et al published an important study regarding this issue in 2013. The study enrolled 
patients previously successfully treated with HALO RFA who underwent 
endoscopy with the biopsies of distal and proximal esophagus, as well as healthy 
controls. 80  Biopsy specimens taken from NSE revealed DIS and enhanced 
permeability trough the epithelium, in all of the 13 tested subject treated with RFA. 
Decreased transepithelial electrical resistance was also found indicating defective 
barrier function of NSE. Having in mind that all of those patients were treated with 
PPI on regular daily basis, and with knowledge of pathogenic role of bile salts in 
weakly acid media, which PPI’s create, one must consider that behind 
morphogenic changes inside NSE is an ongoing weakly acid reflux. 
The bottom line of our study is to show how the different post RFA treatment 
modalities will affect NSE, both in the term of IM and LGD regression as well as 
the recurrence, and in the term of morphological NSE characteristics, preferably 







































1. To evaluate the safety and efficacy of endoscopic radiofrequency ablation 
procedure in the term of early and late procedure related complications, as well 
as primary outcomes regarding the complete eradication of Barrett’s 
esophagus. 
2. To analyze the baseline data obtained from endoscopic and stationary 
manometry studies, with regard to their potential impact on the treatment 
outcomes. 
3. To overview the potential factors contributing to the treatment feasibility and 
outcomes, especially having in mind potential recurrence of Barrett’s 
esophagus after successful radiofrequency procedure. 
4. To make the comparative analysis of different post RFA treatment strategies 
(proton pump inhibitors treatment on one hand, and laparoscopic antireflux 
surgery on other), with special emphasis on the their role on potential 
recurrence prevention. 
5. To evaluate the efficacy of electron microscopy in obtaining the structure of 
neosquamous epithelium (the one that arose from ablated columnar Barrett’s 
epithelium). 






































This was prospective clinical study initiated in November 2009 and conducted at 
the Department of Esophagogastric Surgery, First Surgical University Hospital, 
Clinical Center of Serbia, School of Medicine, University of Belgrade. The study 
was conducted in collaboration with the Institute for Histology, School of Medicine, 
University of Belgrade. Hospital Board and School of Medicine, Ethics Committee 
approved the study and the included patients gave their signed consent. 
 
3.1. Inclusion and exclusion criteria 
 
The following inclusion criteria were applied: 
1. Histologicaly proven Barrett esophagus 
2. Documented history of GERD> 5 years 
3. Age 18 – 75 




The first aforementioned criteria was obligatory, and patient had to met minimum 3 
other criteria to be included in the study. If the case that entry histology was low-
grade dysplasia (LGD), all of the other criteria were not taken into consideration 
and the patient advanced trough the study protocol. If LGD was present, second 
biopsy and pathohistological confirmation were obligatory. 
 
The following exclusion criteria were applied: 
1. Presence of reflux esophagitis LA gr C and D 
2. Presence of peptic strictures of esophagus 
3. Presence of caustic stricture or stricture of any origin 
 
The prospective data base was created and it included: patients demographics, 
symptom score, data gained from upper GI endoscopy and esophageal stationary 
manometry, as well as the data related to HALO RFA procedure and post 
procedural follow-up. For the assessment of BE, endoscopy was performed in our 
Institution, with obligatory biopsies of columnar esophageal epithelium. Dedicated 
pathologist in the field of digestive pathology performed the patohistology 
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analyses. Prague C&M classification was used for the grading of BE extent. In this 




Regular follow-up encompassed endoscopy 8 weeks after RFA procedure, and 
subsequent RFA in case of residual BE which was conducted three months after 
the first RFA session. Residual BE was diagnosed if there were macroscopic signs 
of columnar epithelium in tubular esophagus, confirmed with pathohistologic 
finding of intestinal metaplasia (IM) or LGD. Complete eradication of BE was 
considered if there were no signs of macroscopically present columnar epithelium 
in tubular esophagus, or evidence of IM or LGD on regular biopsy specimens 
which were taken separately from tubular esophagus and at the level of newly 
formed squamocolumnar junction (NSCJ). 
We extracted those patients who had complete eradication (CE) of BE. These 
patients were further enrolled in follow-up protocol including endoscopies with 
biopsies on 6 months, 1 and 2 years. Patients having at least two control 
endoscopies with biopsies were classified in the group with complete follow-up 
data. 
Further, those patients with CE of BE we divided in two groups according to the 
post RFA treatment. One group of patients was treated with daily PPI 
(Esomeprazol 40 mg per day) while others were submitted to laparoscopic Nissen 
fundoplication (NF) after or synchronous with RFA procedure. The allocation of 
patients was performed in following manner: Both treatments modalities after RFA 
(PPI therapy and Nissen fundoplication) were presented in detail to patients and 
were described to be equal both in the term of neosquamous epithelium protection 
and symptom control. So, basically, the post-RFA treatment modality was patient’s 
preference.  
Those patients having macroscopically visible columnar epithelium in tubular 
esophagus and histologicaly proven IM or LGD at any follow-up point were 
considered to have BE recurrence. If the macroscopically visible island of 
columnar epithelium was noted at the level of tubular esophagus it was consider 
as recurrence, regardless of histology obtained. If the macroscopically visible 
columnar epithelium was found at the level of NSCJ or as a columnar tongue 
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above the NSCJ, the pathological confirmation of IM or LGD was obligatory 
parameter for confirmation of the recurrence. For those patients data were taken 
regarding the recurrence timing, as well as pattern of recurrence on tubular 
esophagus or NSCJ. If present in follow-up biopsies, subsquamous intestinal 
metaplasia was separately noted. 
 
3.3. HALO RFA procedure 
 
The RFA procedure was conducted with HALO 90 and 360 systems (HALO 360 or 
HALO 90, Covidien, Sunnyvale, CA, USA). HALO RFA system consists of 
generator unit, which produces energy in dose of 10-12J/cm2 (10 J/cm2 was used 
for patients with IM, and 12 for patients with LGD) and specially designed 
catheters. The energy was applied trough the catheters covering approximately 
one fourth of esophageal circumference (HALO 90), or whole esophageal 
circumference (HALO 360). Procedure was carried in analgosedation for HALO 
90, and general endotracheal anesthesia for HALO 360 procedure. Maximal extent 
of circumferentially treated BE mucosa in one RFA session was 6 cm. If residual 
BE was detected, next RFA session was performed with minimum 3 months apart 
from the last procedure. The details of the procedure are presented in the 
introduction section. 
 
3.4. Antireflux surgery 
 
Laparoscopic Nissen fundoplication was performed in a standardized fashion by 
the same surgical team. Patient was placed in dorsal position, legs spread apart. 
Operating surgeon is positioned between patient’s legs. First 10 mm port was 
placed with Hasson open approach, 2 cm left of the midline, at the middle of 
distance from umbilicus to processus xifoideus. Three working ports are placed , 
followed with Nathanson liver retractor. Briefly, pars densa of hepatogastric 
ligament was dissected, and right crus of the esophageal diaphragmatic hiatal 
orifice was visualized. Esophagus was dissected, encircled, and after a hiatal 
closure and dissection of short gastric vessels “floppy” Nissen fundoplication was 
created with three non-absorbable sutures and without the utilization of the bougie. 
In case that anatomy of gastric fundus was favorable, Rosseti modification of 
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Nissen fundoplication was performed, without dissection of short gastric vessels. 
Synchronous RFA with HALO 360 was performed after complete dissection and 
encirclement of the esophagus, and HALO catheter was positioned under the 
combined vision of laparoscope and endoscope. Usually, in those cases type II 
esophageal dissection was necessary in order to get the sufficient abdominal 
length of esophagus. 
 
3.4. Transmission electron microscopy analysis of intercellular spaces in 
epithelium of eosophageal mucosa 
 
A separate analysis of biopsy specimens was obtained from patients in whom 
complete eradication of BE was achieved with one, or several RFA sessions. The 
basic inclusion criteria were CE-IM and minimal period from the last RFA session 
of 6 months.  
Endoscopic biopsy specimens were taken with “jumbo” forceps. In each patient 
two specimens were obtained from neosquamous epithelium (3 cm above the 
distal margin of palisade vessel zone, or 3 cm above the top of the gastric folds) 
and from proximal esophageal segment (5 cm below the level of upper 
esophageal sphincter).  
Biopsy samples were fixed with 3% glutaraldehyde in cacodylate buffer and 
postfixed in 1% OsO4. After dehydration in graded alcohols, cells were embedded 
in Epoxy medium (Sigma-Aldrich, 45345). Thin sections were mounted on copper 
grids (Sigma-Aldrich, G4901), and stained with uranyl acetate and lead citrate for 
examination on an electron microscope (Morgagni 
268D, FEI, Hillsboro, OR). The sections and micrographs for the analysis were 
selected by using Systematic Uniform Random Sampling. 81  The intercellular 
spaces were measured as distances in between 80 cells, on 10 micrographs per 
sample at 2800x magnification by the use of TEM. The same micrographs were 
used for fractional volume analysis as previously described using the following 
formula: volume fraction = ∑PAP/ ∑Pcyt x ρ, where ∑PAP is the number of points 
of a dense grid counted on intercellular spaces, ∑Pcyt the number of points of a 
second grid counted within the cytoplasm, and ρ is the number of points on the 
dense grid that represent each point of the grid used for the cytoplasm (in this 
case 25).  
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3.5. Statistical analysis 
 
Data are expressed in mean and median values. Fisher’s exact test, Student’s t-
test and Kruskal-Wallis one-way analysis of variance test were utilized. We used 
one-way ANOVA as well. Logistic regression was used to assess to assess the 
potential predictors of BE recurrence and the potential predictive factors for the 
development of the dilated intercellular spaces. Point of statistical significance was 






























There were overall 56 patients who met eligibility criteria and entered the study. 
Out of this number majority were males, 39 patients (69.6%). There were 17 
female patients included (30.4%). 
Mean age of the patients at the moment of their inclusion in the study was 47.3 ± 
10.8, ranging from 18 till 74. Majority of patients were older than 50 years, 39 of 
them (69.6%) 
There were 42 patients who had previous history of smoking (75%), out of those 
29 (51.8%) were active smokers at the moment of inclusion. 
Mean value of body mass index (BMI) of included patients was 29.7 ± 6.1. 32 
patients (55.3%) had their BMI in range from 25 – 30. BMI over 30 was present in 
11 patients (19.6%). 
Family history of upper GI cancer was reported by 4 patients (7.1%). Esophageal 
adenocarcinoma was not reported in family history by any patient. All four of the 
patients reported family history of gastric cancer. 
The duration of GERD symptoms was observed in the 3, 5 and 10 year period. 
Duration of GERD symptoms > 3 years was present in 48 (85.7%) of patients. In 
41 of them GERD symptoms were present for more than 5 years, and in 23 
(41.1%) GERD symptoms were present for more than 10 years. 
History of antisecretory drugs utilization was reported by 53 patients (94.6%). 
Majority of those had prior history of proton pump inhibitors intake, which was 
present in 46 patients (82.1%). 
The basic demographic data and the data related to GERD history are presented 













Table 1. Basic demographic and clinical data  
№ of patients 56 
Male to female ratio 39 / 17 
Mean age 47.3 ± 10.8 
BMI 29.7 ± 6.1 
Smoking history 42 (75%) 
Anamnesis of family upper GI cancer  4 (7.1%) 
Anamnesis of  > 3 years of GERD symptoms 48 (85.7%) 
 
 
4.2. Preprocedural upper GI endoscopy, esophageal stationary manometry 
and Barrett’s histology  
 
Upper GI endoscopy was performed in our Department before the procedure in all 
of the patients included in the study. We utilized the Prague C&M classification. 
According to those mean value of M length in this patients group was 4.3 ± 2.1, 
ranging from 1 to 12. Mean value of C length was 3.1 ± 1.4, ranging from 0 to 10. 
(Table 2.) 
Hiatal hernia was present in 49 patients (87.5%). Hiatal hernia of 3 and more cm in 
size was present in 25 (44.6%) of the patients. In this subgroup, 19 patients had 
type I hiatal hernia, while in 6 of them type III hiatal hernia was present. 
Erosive esophagitis was present in 19 (33.9%) of patients at the study entry. 
According to LA classification grade A esophagitis was present in 12 (21.4%), and 
LA grade B in 7 of patients (12.5%). Healing of esophagitis prior to HALO RFA 
procedure was obligatory endoscopic criteria. 
The entry BE histology was obtained in all patients. Intestinal metaplasia (IM was 
present in 38 (67.9%) of patients, while 18 patients had proven low-grade 
dysplasia (LGD). (Table 2., Figure 1.) Regarding the entry histology distribution of 









Figure 1. Stratification of Barrett’s esophagus patients according to the entry histology 
 
In patients with IM, hiatal hernia>3 cm was present in 14 patients (36.8%), and in 
11 patients who had LGD (61.1%). There was a statistically significant higher 
incidence of larger hiatal hernias in patients with LGD opposed to those with IM 
(p=0.021, p<0.05). Mean value of M length in patients with IM was 4.4 ± 2.0. Mean 
value of M length of BE in LGD group was 4.1 ± 2.3. There was no statistical 
difference in the term of M length of BE between patients with IM and LGD. Mean 
value of C length in patients with IM was 3.3 ± 1.4. Mean value of C length of BE 
in LGD group was 2.8 ± 1.2. There was no statistical difference in the term of C 
length of BE between patients with IM and LGD. 
Mean value of lower esophageal sphincter pressure measured by stationary 
esophageal manometry was 4.2 ± 2.9 mmHg. Ineffective esophageal motility (IEM) 
was present in 37 (66.1%) of the patients. With regard to IEM classification, 29 
patients had amplitudes of distal esophageal contractions <30mmHg, 5 were 
presented with non -propulsive contractions, and 3 with low amplitude 









Figure 2. Stratification of Barrett’s esophagus patients according to the effectiveness of 
the esophageal motility measured by stationary esophageal manometry 
 
Regarding the BE histology, mean value of LES basal pressure among patients 
with IM was 4.3 ± 3.1 mmHg and mean value of LES basal pressure among 
patients with LGD was 4.1 ± 2.6 mmHg. IEM was present in 22 patients (57.8%) 
with IM, and in 15 (83.3%) with LGD.  
There was no statistical significance regarding the mean values of LES basal 
pressure between patients with IM and LGD. There was a statistically significant 
higher incidence of ineffective esophageal motility in patients with LGD opposed to 
those with IM (p=0.017, p<0.05). 
 
Table 2. Preprocedural upper GI endoscopy, esophageal stationary manometry and 
Barrett’s histology data 
No of patients 56 
median M length (cm) 4.3 ± 2.1 
median C length (cm) 3.1 ± 1.4 
BE histology IM 38 (67.9%) 
BE histology LGD 18 (32.1%) 
presence of hiatal hernia 49 (87.5%) 
Pts with HH > 3 cm 25 (44.6%) 
mean lower esophageal sphincter pressure 4.2 ± 2.9 mmHg 








4.3. Data related to HALO RFA procedure 
 
 
HALO 360 RFA procedure was applied as a primary procedure in 20 patients, 
while in 36 primary procedure choice was HALO 90.  
Mean duration of the HALO 360 procedure was 24.1 ± 3.4 minutes. Mean duration 
of HALO 90 procedure was 18.3 ± 3.4 minutes. All of the HALO 360 procedures 
were performed in general endotracheal anesthesia. HALO 90 procedure was 
performed in analgosedation in 25 patients and in general endotracheal 
anesthesia in 2 patients. 
There were no procedure related complications, both in HALO 360 and HALO 90 
groups of patients. 
Most common side effects of the HALO procedure were: post procedural chest 
pain, which was present in 39 patients (69.9%). Mean duration of postprocedural 
chest pain was 2.3 ± 1.2 days. Post procedural dysphagia occurred in 21 patients 
(37.5%). Mean duration of dysphagia was 11,5 ± 6.1 days, and it resolved 
spontaneously in all patients. Mean length of hospital stay after RFA HALO 
procedure was 1.2 ± 0.2 days. 
The majority of the patients (30 patients, 53.6%) received additional HALO 
procedure for residual segments or islands of BE. HALO 360 RFA was employed 
in 11 patients as a second choice procedure, and in two of them as a third choice 
procedure. HALO 90 RFA was employed as a second line treatment in 23 
patients, in 10 patients as a third line treatment, and in 2 patients as a fourth line 
treatment. One patient received 5 HALO RFA sessions. 
In one patient where HALO 360 for LGD C1M3 was applied in 12J/cm2 regimen 
stricture developed, but without need for dilatation. This patient was treated with 
proton pump inhibitors after the procedure. 
The data regarding the number and type of HALO RFA procedure, and side 









Table 3. HALO RFA – type and number of procedure 
Choice of procedure HALO 360 HALO 90 
Primary HALO RFA procedure 20 36 
Second HALO RFA procedure 11 23 
Third HALO RFA procedure 2 10 
Fourth HALO RFA procedure 0 2 
Fifth HALO RFA procedure 0 1 
 
Table 4. HALO RFA related side effects 
HALO procedure side effects Chest pain N Dysphagia N  
Incidence N (%) 39 (69.9%) 21 (37.5%) 
Duration (days) 2.3 ± 1.2 11,5 ± 6.1 
 
 
4.4. Laparoscopic Nissen procedure 
 
 
Laproscopic Nissen fundoplication (LNF) was performed in 22 patients. 
There was no intraoperative complications, or conversions to open procedure. 
The mean duration of LNS was 56.1 ± 11.4 minutes.  
There were no postoperative intrahospital complications. Mean duration of hospital 
stay 2.8 ± 1.1 days. 
In 4 patients LNF concomitant with HALO 360 procedure was performed. There 
were no procedure related complications. The mean duration of concomitant 
LNF/RFA procedure was 85.4 ± 24.8 minutes. 
The most common adverse effect of LNS was postoperative dysphagia which was 
reported by 18 patients (81.8%). 10 (45.4%) of those had dysphagia that lasted up 
to 10 days, in 6 patients (27.2%) duration of dysphagia was up to one month, and 
in two patients (9.1%) it lasted up to three months. 
There was no need for medical interventions due to severe or persistent LNF 
related dysphagia. 
Second most common adverse effect of LNS was postoperative bloating which 
was present in 13 patients (59.1%). In 7 patients (31,8%) bloating symptoms 
resolved up to six months after surgery. In 6 patients (27.3%) bloating symptoms 




4.5. Endoscopic follow-up 
 
Out of the primary included 56 patients, complete resolution of BE was obtained in 
47 of them (83.9%). Regarding the BE histology complete eradication of IM was 
achieved in 33 patients (86.2%), and in 14 patients with LGD entry histology 
(77.7%). 
Analysis of 9 patients in whom complete BE eradications was not achieved was 
made. 
There were 5 patients with IM (55.6%), and 4 patients with LGD (44.4%) in whom 
complete response was not obtained. Second HALO RFA session was performed 
in 8 of them. In one patient, only single HALO 360 procedure was performed due 
to pronounced post procedural esophagitis and poor compliance to medications 
prescribed. 
In 5 patients residual BE was presented in form of multiple islands of BE mucosa, 
in 3 as a residual circumferential BE segment, and in 2 combination of residual 
circumferential segment and multiple islands of BE. 
Extreme dilatation of the esophagus was seen in one of these nine patients 
(11.1%). This patient had morbid obesity as well, with BMI being measured at the 
study entry 46.1. After two sessions of RFA patient was put on list for gastric by 
pass surgery, which was successfully performed afterwards. 
Other baseline patient’s characteristic such as age, gender, GERD duration, hiatal 
hernia size, presence of IEM did not significantly statistically differ from the 
baseline characteristics of the whole study population. (Table 5.) 
 
Table 5. Baseline characteristic of patients with residual BE 
№ of patients 9 
Male to female ratio 6 / 3 
Mean age 42.9 ± 15.1 
BMI 33.8 ± 9.6 
Smoking history 7 (77.8%) 
Anamnesis of family upper GI cancer  0 
Pts with HH > 3 cm 5 (55.6%) 
Pts with ineffective esophageal motility 4 (44.4%) 
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4.6. Stratification according to post RFA treatment 
 
 
Patients with complete eradication of BE were divided according to the study 
protocol in two groups regarding the post RFA treatment option. 
There were 25 patients treated with PPI after HALO RFA, and 22 submitted to 
laparoscopic Nissen fundoplication (LNF). Out of 22 patients who underwent LNF, 
4 were operated concomitant to first HALO RFA session. 
In the group of patients receiving PPI’s treatment after HALO RFA, there were 17 
males and 8 females. Mean age of this study group was 48.1 ± 12.4. Mean value 
of BMI in this group was 30.1 ± 3.4. Mean number of HALO RFA procedures in 
this group was 2.3. IM was present in 18 and LGD in 7 patients. Median values of 
C and M length were 2.9 ± 1.1 and 3.9 ± 1.7, respectively. Hiatal hernia bigger that 
3 cm was present 12 (48%) of the patients. (table 6, figure 3) 
 
Table 6. Demographic, endoscopic and RFA related data in patients with CE BE 
distributed in two groups regarding the post RFA treatment 
 HALO RFA + 
PPI’s 
HALO RFA + 
LNF* 
p value 
No of patients 25 22  
mean age 48.1 ± 12.4 45.4 ± 15.2 0.677 
gender (male to female ratio) 17/8 15/7 0.768 
BMI 30.1 ± 3.4 28 ± 4.1 0.341 
mean No of RFA procedures 
pp* 
2.3 2.1 0.451 
BE histology (IM/LGD) 18/7 15/7 0.243 
BE C length 2.9 ± 1.1 2.6 ± 1.3 0.407 
BE M length 3.9 ± 1.7 3.8 ± 1.4 0.377 
HH* size > 3 cm N(%) 12 (48%) 12 (54.4%) 0.385 
 
In the group of patients who underwent LNF treatment after HALO RFA, there 
were 15 males and 7 females. Mean age of this study group was 45.4 ± 15.2. 
Mean value of BMI in this group was 28 ± 4.1. Mean number of HALO RFA 
procedures in this group was 2.1. IM was present in 15 and LGD in 7 patients. 
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Median values of C and M length were 2.6	±	1.3	and 3.8	±	1.4, respectively. Hiatal 
hernia bigger that 3 cm was present 12 (54.4%) of the patients. (table 6, figure 3) 
There were no statistical differences in term of gender distribution, age and mean 
BMI between the groups (table 6, figure 3). 
Also, there were no statistical differences regarding the mean number of RFA 
procedures employed, BE histology (IM/LGD ratio), C and M length of BE, as well 
as percentage of patients with hiatal hernia size > 3cm. (table 6, figure 3) 
	
 
Figure 3. Comparison of demographic, endoscopic and RFA related data in patients with 
CE BE distributed in two groups with regard to the post RFA treatment 
	
4.7. Recurrence of BE  
 
The criteria for complete follow-up were met by 40 (85.1%) of those with complete 
eradication of BE. The remaining 7 patients had one follow-up endoscopy with 
biopsies after CE-BE. After 2 year of prospective follow-up BE recurrence was 
noted in 5 patients (20%) treated with PPI’s, and 2 patients (9.1%) who underwent 
LNF (figure 4). In those treated with PPI’s we marked 4 recurrences of IM and one 

















Figure 4. Distribution of the patients with regard to the type of post RFA treatment and 
incidence of BE recurrence 
 
With regard to the recurrence timing, in PPI’s group recurrence was marked in 1 
patient after 6 months, 2 after one year and in 2 after two years. Mean time from 
last RFA session till recurrence detection in PPI’s group was 482 days (range from 
173 to 812 days). In LNF group 2 patients were found to have recurrent BE on 2  
years surveillance endoscopy, in one it occurred after 730, in other 851 days after 
last HALO RFA session. (Table 7.) 
	
Table 7. Timing of recurrence according to different post RFA treatment modalities 
 RFA + PPI’s RFA + LNF 
6 months 1 0 
1 year 2 0 
2 years 2 2 
	
With regard to pattern of recurrence, in PPI’s group in 4 patients recurrent BE was 
noted both in tubular esophagus and at the level of NSCJ. Also it was present in 
two or more biopsy specimens in all 5 patients with recurrent BE. 
In LNF group one recurrent BE was noted at the level of tubular esophagus, and 
one on the level of NSCJ. In one patient it has been proven in more than two 

















We found no recurrence of BE underneath neosqouamous epithelium (this was 
also confirm in selected subgroup of patients after evaluating jumbo forceps 
biopsy samples on electron microscopy, see Results chapter: Morphological 
characteristics of neosquamous epithelium). 
	
Table 8. Pattern of recurrence according to different post RFA treatment modalities 
 RFA + PPI’s RFA + LNF 
Tubular esophagus 1 1 
NSCJ 0 1 
Tubular esophagus+NSCJ 4 0 
	
Comparison was made between the groups regarding the overall incidence of the 
BE recurrence. There was no statistical difference between the incidence of BE 
recurrence regarding the post procedural treatment option (p=0.423, p>0.05). 
(Table 9.) 
 
Table 9. The recurrence of BE after RFA in patients treated with PPI’s or Nissen 
fundoplication in 2 year follow-up 
 no recurrence recurrence p value 
HALO RFA + PPI’s n(%) 20 (80%) 5 (20%) 
0.423 
HALO RFA + LNF n(%) 20 (90.9%) 2 (9.1%) 
 
Different demographic patient’s characteristic and patients endoscopic baseline 
characteristics were also evaluated with regard to recurrence of BE. Gender was 
not shown to be statistically significant in the term of recurrence (p=0.768, P> 
0.05), as well as age (p= 0.677, p>0.05). This was also case with hiatal hernia size 
(cut-off value>3 cm), BE C&M length, p values: 0.385, 0.407 and 0.377, 








Table 10. Demographic and baseline endoscopic characteristics influence on overall rate 
of BE recurrence after HALO RFA and with regard to post procedural treatment 
 RFA + PPI’s RFA + LNF p value 
Gender 
0.768 Male (%) 68.0% 63.6% 
Female (%) 32.0% 36.4% 
Mean age (years 47.4 46.0 0.677 
HH> 3 cm (%) 44.0 59.1 0.385 
BE C length (mean, cm) 2.9 2.6 0.407 
BE M length (mean, cm) 3.9 3.8 0.377 
Recurrence, n(%) 5 (20%) 2 (9.1%) 0.423 
 
When we extracted the patients with BE C&M>4 cm we found statistical difference 
between the groups in favor of LNF group (p= 0.021, p<0.05). All the patients with 
BE recurrence in PPI’s group had C length of BE >4 cm. In LNF group 8 patients 
had C length of BE > 4 cm, 2 of those had recurrent BE after 2 years. (Table 10) 
 
Table 11. The recurrence of BE after RFA in patients with BE C length≧4cm treated with 
PPI’s or LNF  
 no recurrence recurrence p value 
HALO RFA + PPI’s n(%) 0 5 (100%) 
0.021 










Figure 5. The comparison of the  recurrence rates of BE after RFA in patients with BE C 
length 	4cm with regard to the post RFA treatment 
 
We extracted the factors which had a strong correlation with the BE recurrence 
after HALO RFA. Those were size of hiatal hernia (cutoff >3 cm), and the length of 
BE (C&M criteria). (table 11) 
	
Table 12. Factors influencing recurrence of BE after RFA 
 no recurrence recurrence p value 
Hiatal hernia size 
0.012 <3cm (%) 85.7% 14.3% 
>3cm (%) 70.8% 29.2% 
BE M length (mean, cm) 2.4 4.4 <0.001 
BE C length (mean, cm) 3.2 5.6 <0.001 
 
4.8.Transmission electron microscopy 
 
Overall, 20 patients in which CE-IM was achieved underwent specific biopsy 
protocol for transmission electron microscopy evaluation. In 11 of them complete 













The basic demographic data, the data regarding the upper GI endoscopy and 
stationary manometry at the study entry are shown in the table 13. There were no 
differences in the term of age, gander, nor in the term of the mean length of BE 
segment or mean values of lower esophageal sphincter. 
The mean value of IS length in the patients with CE-IM under the PPI’s regimen 
was 0.734µm ± 0.325 and 1.262 ± 0.174 µm in the proximal esophagus and NSE, 
respectively. 
The mean value of IS length in the patients with CE-IM who underwent antireflux 
surgery was 0.378 ± 0.116 µm and 0.879± 0.329 µm in the proximal esophagus 
and NSE, respectively. 
With the regard of the proposed cut-off value for the non pathologic length of IS, all 
of the patients treated with PPI’s had DIS in NSE, and 4 out of 5 had DIS at the 
level of proximal esophagus. In the group of patients who underwent antireflux 
surgery 3 patients had DIS in NSE (50%), and 2 of them had DIS in proximal 
esophagus (33.3%). 
The comparative analysis of the IS lengths was made according to the post RFA 
therapeutic regimen. We found no statistical difference among the mean IS values 
in NSE, although there was statistical tendency favoring the antireflux surgery.  
The mean values of IS length in proximal esophagus were statistically significantly 
lower in the group of patients who underwent antireflux surgery. 
The mean values of IS length inside NSE and proximal esophagus are presented 
in table 13. 
 






RFA + LNF 0.378 ± 0.116 0.879± 0.329 
RFA + PPI’s 0.734 ± 0.325 1.262 ± 0.174 
P value .003 .06 
 
Fractional volume analysis showed that percentage of IS with the regard to whole 
thickness of NSE in the group of patients treated with PPI’s was 27.82%. (range 
from 20.1 till 38.9%). The percentage of IS inside the squamous epithelium of 
proximal esophagus was 16.93% (range from 11.58% till 20.48%). 
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Fractional volume analysis showed that percentage of IS with the regard to whole 
thickness of NSE in the group of patients undergoing antireflux surgery was 
22.23% (range from 15.52 till 42.57%). The percentage of IS inside the squamous 
epithelium of proximal esophagus was 15.35% (range from 12.86% till 18.03%). 
No statistical differences were found when IS volume percentages were compared 





































Barrett esophagus remains filed of great controversies, starting from its definition, 
over the course of disease evolution, till the issue of treatment. Still, somehow it 
seems that with the introduction of HALO system things change towards better, as 
we gained effective weapon to safely treat BE. Although showed to be extremely 
effective, HALO is still relatively new method, and years must pass, before medical 
public generates definitive judgment.  
This study addressed the patients with intestinal metaplasia and low-grade 
dysplasia. The intent of the study was to show how effective and durable is HALO 
RFA in complete eradication of IM and LGD. The second basic study goal was to 
evaluate the effect of post RFA treatment regarding the disease recurrence 
prevention, with special emphasis over morphologic characteristic of 
neosquamous epithelium. 
The inclusion criteria of the study were created with the respect of so far proven 
risk factors for BE, such as GERD, age>50, obesity and smoking. Basically, all of 
the patients included in the study were those with long lasting GERD, with the 
median GERD symptom duration over 7 years. The percentage of those with 
significant hiatal hernia was also high, over 60%. The obesity was present in over 
20%, while majority of patients had their BMI between 25- 30. There were no 
differences in the term of gender in our study population.  
Endoscopic data revealed high percentage of those with long segment BE, with 
median C values being over 3 cm, and median M values over 4 cm. Median value 
of lower esophageal sphincter basal pressure was approximately 4 mmHg in this 
study, and the majority of patients had marked ineffective esophageal motility. 
These data are in concordance with the majority of studies showing baseline 
characteristics of BE patients. It has repeatedly being shown that BE patients as a 
subset of GERD cohort, have lowest values of LES, poor esophageal motility, and 
more pronounced acid and weakly acid reflux measured by pH and pH impedance 
monitoring. Among the other risk factors hiatal hernia size was shown to be not 
only the risk factor for developing the long segment BE, but also an independent 
risk factor for EAC. 82 A large meta-analysis that included 4390 patients with BE 
found that patients with hiatal hernia had increased risk for long segment BE, even 
after adjusting risks for reflux and BMI. 83 A study by Savarino et al evaluated 
patterns and intensity of reflux in patients with erosive esophagitis, short and long 
segment BE, as well in healthy controls. The authors employed 24 hour 
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pH/impedance monitoring and found that among aforementioned groups patients 
with long segment BE had highest scores on 24 pH monitoring and most defective 
acid clearance opposed to other groups. The subgroup patients with long segment 
BE had significantly more episodes of both acid and non-acid acid reflux, seen on 
impedance tracings than other observed groups.84 Also, it has been documented 
that the BE is the end stage chronic GERD disease, and that vast majority of BE 
patients suffer from some kind of esophageal motility impairment, most frequently 
observed as low amplitude contractions of distal esophagus, and non propulsive 
peristaltic waves.85 
When it comes to assessment of esophageal motility in BE patients, one must ask 
a question whether this is a primary disorder leading to more pronounced GERD, 
or it is a consequence of chronic exposure of esophagus to pathologic reflux. This 
issue was evaluated in two studies from our Department. We have initially showed 
that patients with ineffective esophageal motility (IEM) can be operated safely with 
total Nissen fundoplication, without concern of persistent dysphagia. 86 In the same 
study it has been shown that esophageal motility can recover after antireflux 
surgery, which may be partially induced by complete reflux blockage, and healing 
of esophagus. However, in the second publication a special emphasis was given 
upon subtypes of IEM.87 It was shown that some of those patients do not have 
benefit from antireflux surgery, in the term of motility recovery, and the conclusion 
was that the origin of IEM might be different among three subtypes. So, high 
incidence of IEM among BE patietns could have two implications. Firstly, the long 
lasting GERD causes metaplasia of espophageal epithelium, and leads to more 
deeper injuries of esophageal wall, leading to ineffective esophageal motility, 
which on the other hand contributes to severity and frequency of GER. Secondly, if 
IEM exists combined with BE, than the treatment with PPI’s will probably be 
insufficient for these patients, as it will not improve esophageal clearance, nor will 
stop the weakly acid reflux. 
So far published data showed high efficiency and safety of HALO radiofrequency 
ablation in the treatment of BE. The results of our study matched these findings. 
During the study period, there were no complications related to the procedure, 
such as perforation or bleeding. The most common adverse effects were 
retrosternal chest pain and dysphagia, which completely resolved in 10 days after 
the procedure. The rate of the stricture was also extremely low. The stricture was 
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present in only one patient, and it did not require endoscopic dilatation, or other 
kind of invasive intervention. The patient complained of mild dysphagia, which was 
treated satisfactory with PPI’s in combination with prokinetics. Another stricture 
was noted in one young patient with 12 cm long BE segment, which had 
developed esophageal stricture prior to the RFA procedure. The stricture was at 
the level of proximal thoracic esophagus and it did not progress after the initial 
HALO treatment. The area of stricture was not treated with HALO 360 initially, due 
to inability for adequate balloon calibration. After LNF and initial HALO RFA 
procedure were performed, second HALO RFA lead to complete resolution of BE. 
The so far published studies with long-term follow-up of patients after HALO RFA 
also point out a high safety of the procedure. In the study, which evaluated the 
durability of HALO RFA for patients with dysplastic, BE, authors also presented 
the data regarding the safety profile of procedure.88 These data have even more 
value, because the study covered the patients with dysplasia, which is more 
demanding group to treat. In this study, authors noted 4 serious adverse effects 
(3.4%). Those were: one serious upper GI bleeding in patient undergoing 
antiplatelet therapy, and three overnight hospitalization due to the onset of chest 
pain. The perforation rate was zero. However, authors reported that 7.6% of 
patients developed esophageal stricture, which was diagnosed with endoscopy, 
with or without dysphagia. In all patients dysphagia resolved, with mean 2.8 
dilatation sessions per patient. In the study of Velanovich post RFA strictures 
occurred in patients with extremely long segment BE, more than 12 cm in length in 
3 cases, and more than 6 cm in one case. 89 The author calls for special attention 
in those patients. According to Fleischer among the published series utilizing the 
HALO treatment, chest pain seems to be most common side effect, and it usually 
lasts for several days. In 1- 2% of patients chest pain is more intense and 
eventually will require readmission hospitalization. Esophageal strictures occur 
rarely, and usually are related with previous esophageal mucosal resection. In the 
review of over 20 000 cases, incidence of esophageal strictures was 1%, and no 
mortality related to HALO RFA procedure was recorded.72 
Controversies still persists regarding the application of HALO RFA procedure for 
patients with non-dysplastic BE. There are observations that there are no 
evidences to justify this, because the risk of progression in patients with IM is low, 
and surveillance strategies should be employed. This standpoint is more 
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supported with the data indicating substantial risk of BE recurrence and presence 
of buried glands after RFA, visualized with novel endoscopic visualization 
techniques. 90, 91 There is even a study showing that RFA for non-dysplastic is not 
cost-effective in term of reducing the risk of progression. Same study proved the 
cost effectiveness of RFA in the treatment of LGD and HGD. 92 The rationale for 
RFA in non-dysplastic BE can be supported with the following facts, well analyzed 
in the review paper of Akiyama et al. 93 First, it is impossible to foresee which 
patients will progress to HGD and EAC, and the timing of progression trough the 
course of disease is unpredictable. Second, there is a risk of misdiagnosis due to 
the sampling error, interobserver disagreement and poor compliance with 
surveillance protocols. Third, the physicians must be aware of the anxiety and 
cancerophobia in patients diagnosed with BE. It is sensible to propose RFA 
procedure to patients with non-dysplastic BE, after the careful evaluation of 
aforementioned facts, and the risks present in each individual patient. The safety 
profile, efficacy and proven decrease of risk progression, favor the RFA procedure 
over surveillance protocols, and justify it’s implementation in patients with non-
dysplastic BE. 
One of the basic goals of our study was to evaluate the efficacy of HALO RFA 
procedure in complete eradication (CE) of intestinal metaplasia and LGD. During 
the course of the study CE of BE was found in 86.2% and 77.7%, for IM and LGD, 
respectively. We tried to analyze the possible causes of residual BE. In 4 patients 
the explanation behind failed RFA could be dilated distal esophagus. These 
patients were offered with concomitant HALO/LNF, but they have chose PPI’s 
treatment instead. It is the opinion of our group that patients with dilated 
esophagus cannot be successfully treated with RFA, because the RFA electrode 
will not have proper contact with the mucosa. In one patient with long segment BE, 
HALO 360 procedure did not lead to satisfactory outcomes, although this patients 
did have normal diameter of the esophageal lumen. The poor compliance with the 
medications could be the potential cause in this case. In others, ongoing reflux 
despite therapy, or in one case even LNF, was probable cause of failed RFA. 
When evaluating the extent of BE, especially in its most distal segments and in the 
presence of hiatal hernia, one must have in mind the concept of “dilated distal 
esophagus”  (DDE), proposed by Chandrasoma and DeMeester. 94 According to 
this logic and well-proved standpoint, the proximal extent of gastric folds and 
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cardia are in fact dilated esophagus, transformed during time into the columnar 
lined transition zone. In the presence of GERD, this “dilated distal esophagus” is 
often being misinterpreted as proximal stomach and gastric folds, although it 
probably is columnar lined esophagus. The only method by which one can 
righteously make a proper judgment is to take the biopsy samples from this region. 
Cardiac mucosa and oxyntocardiac mucosa should be “proclaimed” as the dilated 
end- stage esophagus. Trough this concept one can explain the evolution of the 
progressive esophageal dilatation in patients with the long segment BE. Those 
patients represent technical challenge for RFA. The “DDE” idea was nicely 
evaluated in review paper published by Lenglinger and coauthors. 95 They went 
beyond historical misinterpretation of the so-called “cardia” region, and nicely 
structured the article regarding the true origin of esophagogastric junction mucosa. 
If the peritoneal coverage is absent and submucosal glands are present, it is 
obvious we are dealing with esophagus, covered with columnar epithelium. Thus, 
the concept of DDE is so far the best elucidated and documented explanation of 
BE origin. With the introduction of RFA, this concept could be explanation beyond 
the ineffective ablation and high incidence of recurrent IM at the level of cardia. 
Of course, regardless of esophageal dilatation, the most acceptable explanation 
for residual BE after RFA is the ongoing and uncontrolled reflux. The study by 
Krishnan et al. evaluated this aspect in details. 96 This study included 37 patients 
with long segment BE IM, and patients with HGD. After the 3 consecutive ablation 
sessions, patients were divided in the groups with complete response (CR) and 
incomplete response (ICR). 24-hour pH/impedance data showed that those with 
ICR had significantly higher number of weakly acid and weakly alkaline reflux 
opposed to those with CR. Since all patients were given PPI’s in a twice-daily 
regimen, the number of acid reflux episodes did not differ between the groups. 
Same study recognized the size of hiatal hernia and length of the BE to be 
independent predictive factors for incomplete response after RFA. Study by 
Akyama et al was in concordance with these data.97 It was shown that patients 
with normal or mild intraesophageal acid exposure have significantly higher 
probability of achieving CR after RFA opposed to those with moderate and severe 
esophageal acid exposure, measured with 24-hour pH metry. Along with the acid 
exposure, size of hiatal hernia was recognized also as an independent risk factor 
for RFA failure. Some other studies have identified size of hiatal hernia and length 
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of the BE as the most important factors for successful RFA procedure.98 If we 
return to concept of “dilated distal esophagus”, and we have in mind literature 
proofs of negative effect of hiatal hernia on RFA outcome, the rationale for 
antireflux surgery seems to be inevitable. This attitude is even more justified with 
the aforementioned evidences of ongoing weakly acid and weakly alkaline reflux 
despite PPI’s therapy. 
To conclude the discussion about the possible causes of incomplete response 
after RFA for BE, we have to emphasize three basic factors. Those are: ongoing 
reflux, DDE together with hiatal hernia size and length of BE. 
The role of antireflux surgery as an adjunct to RFA procedure, or as a choice of 
post RFA treatment has not been properly addressed in the literature so far. Up to 
now, there are no randomized trials comparing the role of antireflux surgery and 
PPI’s on RFA outcomes. There are several publications until now, however, which 
are valuable to mention and which cover this issue. 
One of those is for sure study conducted by O’Conell and Velanovich. 99 The 
authors included 47 patients in whom RFA was performed for non-dysplastic and 
dysplastic BE. Of those, 19 patients had their fundoplication created before, after 
or concomitant with RFA. The remaining 28 patients were treated with PPI’s. After 
one-year follow-up, the persistent BE was present at one patient with 
fundoplication, and at 7 in whom PPI’s treatment was employed. The patients who 
had fundoplication required lower number of RFA sessions to achieve complete 
eradication of BE, and the majority of them require only a single session. In a 
small study population, Eldaif et al reported 100% complete response rate after 
RFA for IM and LGD. In this report, 11 patients were treated afterwards with 
fundoplication, but due to persistent reflux symptoms during PPI’s treatment, and 
no direct comparison on the RFA outcomes were made 100 Recent report by 
Johnson and colleagues failed to prove advantage of post RFA LNF over PPI 
therapy in terms of BE recurrence prevention. In this study complete eradication of 
IM remained at 70% of patients after fundoplication. However, authors did 
postulate that fundoplication after RFA could be a superior option in preventing the 
further disease progression. 101 
A superior role for antireflux surgery in the light of RFA procedure could be in 
patients with large hiatal hernias, and dilated distal esophagus. This could be 
obtained by employing concomitant laparoscopic antireflux procedure and RFA. 
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Goers et al first described this approach in the literature.102  Their study was 
conducted in 8 patients, of which 6 was presented with major hiatal hernia 
requiring reduction. The procedure was concomitant HALO 360 RFA during the 
laparoscopic fundoplication. RFA was performed after hernia reduction, and 
esophageal encirclement, which affected the esophageal lumen in the manner that 
RFA electrode applied more closely to the mucosa. This kind of approach showed 
that in 5 patients complete eradication of BE was achieved after a single RFA 
session, while the remaining three patients underwent consequent ablation 
session. The rates of procedure related complications were substantially high. One 
patient in this small study group developed stricture, and in one esophageal 
perforation occurred. The cause of perforation may be related to the fact, that in 
this particular patient BE segment was too long to be treated in a single session. 
In our study, concomitant LNF and RFA procedure was proven to be safe. We 
have treated 4 patients in this manner during the course of the study. Procedure 
was not too time consuming, and it was performed in conjunction with the basic 
rules of HALO 360 procedure. Most importantly the esophageal calibration was 
performed after the hiatal hernia had been reduced, esophagus encircled and 
pulled down. That way the potential pitfall of choosing wrong diameter of RFA 
balloon was avoided. Second, no more than 6 cm of BE mucosa was treated in the 
single session. There was no procedure related complications in our study. 
Another interesting observation, which we couldn’t document so far, is that patient 
with concomitant or prior fundoplication, have faster mucosal recovery after RFA, 
observed on the first endoscopic evaluation. It has been noticed in our study that 
patients in whom PPI’s are employed in a twice-daily regimen after RFA, have 
very fragile mucosa 8 weeks after procedure, when first endoscopy is usually 
scheduled. This mucosa is sometimes covered with superficial erosions. In this 
subset of patients we usually add evening dose of H2 blocker, along with previous 
PPI therapy. The higher number of patients is needed to document these 
observations, and more standardization in the term of interobserver agreement. 
We have shown the data regarding the efficacy of RFA treatment, and rates of BE 
complete eradication. Now we must focus on reports regarding the recurrence of 





1. rates of recurrence 
2. timing of recurrence 
3. pattern of recurrence 
 
The issue of recurrence rates was well assessed in the meta-analysis conducted 
by Orman et al. 103  This study included the literature data obtained from 
prospective publications, published before 2011 and in which method of ablation 
was HALO RFA. The studies employing additional ablative treatment or mucosal 
resection were not taken into consideration. Further, all of the included studies 
needed to have data concerning the rates of complete response in the term of IM 
eradication (CR-IM) or dysplasia eradication (CR-D). Minimum 12 months follow-
up was necessary inclusion criteria. The studies, which were subject of this meta-
analysis, came from USA and Europe. There was overall 15 full text articles and 5 
abstracts after the exclusion criteria were applied. Those were the studies 
reporting efficacy, durability and combination of those two. The efficacy analysis 
showed that CR-IM was found in 78% of patients (ranging from 70 – 86%), and 
CR-D in 91% of patients (87 - 95%). During the treatment 9 patients progressed to 
EAC, with the estimated risk ratio of 0.1%. Overall recurrence rate of IM after initial 
CR-IM was 13% (9 - 18%), and it was higher in low quality studies. Recurrence of 
dysplasia was noted in 5 patients, and EAC in 4 patients when analyzing the 
included studies.  
Maybe more comprehensive recurrence analyzes was published by Gupta et al. 91 
This study included patients treated in three referral tertiary centers in the USA. 
There were overall 592 patients, of which 71% had HGD as baseline histology. 
This is the largest prospective study so far, including patients with dysplasia in 
whom RFA treatment was undertaken. In the course of the treatment during 22 
months from first RFA session CR-IM was noted in 56% of patients. Out of those 
patients with CR-IM during the two-year follow-up recurrence of BE was noted in 
33% of patients. In the majority of patients recurrence was histologically noted as 
IM, while in 22% recurrence of dysplastic epithelium occurred. The recurrent cases 
were managed endoscopicaly, but no data were provided regarding the future 
outcome of these patients. In our study, recurrence rate among patients with CR-
IM after two-year follow-up was 14.9%. This value could be implicated with the 
sampling error, especially in the term of cardia region biopsy. However, the 
	
	 52	
patients with visible islands of columnar epithelium on the level of tubular 
esophagus were proclaimed to have recurrence, even without histologic 
confirmation. 
An issue that is hard to address at this point is the timing of recurrence after 
achieving the CR-IM. This is due to the fact that this procedure is generally new, 
and longer follow-up period is needed. The studies addressing timing of 
recurrence after RFA so far, reported in majority of cases 1 and 2 -year follow-ups. 
For example, Shaheen et al report on 3 years follow-up of their group previously 
included in the AIM randomized control trial. 104 The CR-IM was achieved in 75% 
and CR-D in more than 85%, without maintenance RFA. The validity of these data 
is confirmed with the confirmation that depth of biopsy specimens was adequate 
(subepithelium present) in 82.4% of patients. 105 
We tried to analyze the study follow-up period trough the 6 months, one year and 
two years follow-up. The recurrence was marked in two patients inside first six 
months of follow-up period, two inside one-year and three more inside two-year 
follow-up period. Interestingly, earlier occurrence of recurrence was noted in 
patients who were treated with PPI’s, opposed to those who underwent antireflux 
surgery. The statistical analysis of this finding was not achievable due to the 
limited number of patients, and imprecise methodology process, nevertheless it is 
worth wile mentioning. Further analyzes may be forwarded to precise timing of 
recurrence detection with the evaluation of factors contributing to recurrence, 
especially the impact of post RFA treatment.  
Pattern of recurrence is another important issue that needs to be evaluated. It was 
stated by Korst et al that recurrence of BE after RFA treatment my occur in three 
separate modalities, as the recurrence at the level of: 
1. tubular esophagus 
2. gastroesophageal junction 
3. beneath neosquamous epithelium (subsquamous recurrence, or “buried 
glands)106 
In this study authors followed overall 151 patient treated with RFA for metaplastic/ 
dysplastic BE for a median period of 18 months. The group of patients with 
persistent/recurrent IM after RFA treatment was recognized. There were overall 
26% of patients with persistent/recurrent IM. Most commonly in this study group 
recurrence was identified at the level of gastroesophageal junction (10 patients). 
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Both subsquamous presence of IM and recurrent IM at the level of tubular 
esophagus were recognized in three patients. In the retrospective report from 
Vaccaro et al, 47 patients in whom CR-IM was achieved underwent further 
surveillance. 107 Patients were followed for median 13.3 months (5- 38 months), 
with median 2 surveillance endoscopies (range 2- 5) performed at that period. The 
study reported overall rate of recurrent IM to be 31,9%, with cumulative yearly 
incidence being 25.9%. Pattern of IM recurrence in this study was as follows: 73% 
of patients had recurrent IM at the level of gastroesophageal junction, while 27% 
of patients had recurrent IM at the newly recognized islands of columnar 
epithelium on the level of tubular esophagus. The authors draw the conclusion that 
close surveillance after CR-IM with RFA is essential due to very high cumulative 
one-year rate of recurrence. One must be careful when evaluating this study for 
two reasons. Firstly, the high frequency of recurrence detection at the level of 
gastroesophageal junction may be due to the sampling error at the first place, 
meaning that CR-IM was not achieved at all. Secondly, when performing HALO 
RFA one must take special caution at the GEJ level, because HALO RFA 
technique gives us ability of “creator”, the one that forms the new 
squamocolumnar junction. So, with the proper evaluation of the GEJ, the primary 
ablation procedure should probably be extended towards top of the gastric folds, 
and should cover the whole region of so called cardia. This is the point when we 
should think again about the “dilated distal esophagus” concept, and think trough 
the method of ablation again. 
Gupta et al. also evaluated the pattern of recurrence in the previously cited report. 
91 Out of the 37 patients with recurrent IM and dysplasia, in this study, it was 
almost equally found at the level of tubular esophagus and GEJ. The 
subsquamous recurrent IM was not reported in this study. In the dysplasia AIM 
sham control trial, incidence of “buried glands” in those with CR-D was 
approximately 5%. 9 
The incidence of subsquamous IM after RFA is rarely being reported. Grey et al 
conducted a large systematic review of the literature with the intent to evaluate the 
frequency and significance of subsquamous IM in patients previously treated with 
ablative endoscopic procedure. 108 The review covered PDT and RFA methods. 
After 22 reports employing PDT were evaluated, the incidence of “buried glands” 
found to be 14.2%. RFA treatment was assessed trough 18 literature reports, in 
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which 9 patients with proven “buried glands” were found, overall 0.9%. Dutch 
authors conducted an interesting study in order to properly establish the incidence 
of buried glands after RFA treatment. 109  They used the term “pseudoburried 
glands”, for those obtained in biopsy samples from macroscopically visible islands 
of columnar epithelium. The 69 consecutively RFA treated BE patients were 
included in this study. The biopsy samples were taken from normal appearing 
squamous epithelium, and from visible islands of columnar epithelium on tubular 
esophagus. The incidence of subsquamous IM in normal appearing squamous 
epithelium biopsy samples was 0.1%. Biopsy samples of columnar mucosa islands 
revealed high incidence of “buried glands”, which were found in 21% of patients. 
Authors conclude that sampling error must be avoided when reporting the true 
incidence of “buried glands” after RFA. 
The application of the novel endoscopic visualization methods may be helpful in 
identifying the areas of NSE with buried gland hidden underneath. One of such 
methods is an optical coherence tomography (OCT). The basis of this new 
technology is to provide visualization of the 3D tissue ultrastructure. In the study 
applying OCT technology in patients with CR-IM after RFA, the incidence of buried 
glands was stunningly 63%. 90 The fact that majority (approximately 70%) of buried 
glands were found at the level of SCJ, may rise an issue over the adequacy of 
ablation in that area. 
In our study the recurrence was equally found at the level of GEJ and tubular 
esophagus. We did not found recurrence beneath normally appearing NSE. The 
biopsy specimens were taken with jumbo forces biopsy, where lamina propria of 
mucosa could be evaluated in majority of biopsy specimens. These findings were 
confirmed when electron microscopy was performed in selected group of patients 
with CR-IM. 
The other part of this study was based on the electron microscopy evaluation of 
the biopsy specimens taken from neosquamous epithelium. The included patients 
had complete eradication of previous BE IM or LGD achieved in one or more 
sessions of RFA. The idea for such investigation came from study conducted by 
Jovov et al. 74 This study implicated that NSE is a fragile epithelium with dilated 
intercellular spaces and increased permeability. The low expression of claudin-4, 
valuable brick inside tight junctions was also confirmed in NSE. These findings 
were observed in all included patients, previously treated with RFA and in which 
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CR-IM was obtained. The paper by Orlando addresses this publication in details. 
110 Author brings his concern of the increased permeability and defective barrier 
functions of NSE. If NSE would be exposed to pathological acid or even weakly 
acid reflux, and with regard to its weakened defense mechanisms, the recurrence 
of BE may occur. Also, if the buried glands are present beneath NSE, increased 
permeability trough the epithelium could initiate their genetic instability. What 
emerges, as a relevant issue is whether these NSE morphologic characteristics 
are in its true nature, or possible provoked by ongoing reflux. 
The basic intent of our study was to asses the impact of ongoing reflux on NSE. 
The patients included were treated with PPI’s and antireflux surgery after CR-IM 
achieved with RFA. The rationale for this methodology was under the premise that 
fundoplication will mechanically block gastroesophageal reflux, regardless of its 
acidity. Therefore, we might establish whether there are morphological changes 
inside NSE, and to sought out the potential role of ongoing reflux. 
The neosquamous epithelium is a product of re-epithelization after successfully 
performed ablative endoscopic procedure. The basic histology of NSE resembles 
the one of native squamous epithelium. One to two basal cell layers, followed by 
multiple layers of more mature cells, form NSE. In the early post-ablation phase, 
hyperplasia of the basal layer and lamina propria papilla elongation may be 
present, indicating the regenerative reflux induced changes. 111 The origin of NSE 
is not clearly established. It is noted that it may originate from new post ablation 
SCJ, or from the remnant cell laying underneath of BE, and/or from esophageal 
glands. 112 Paulsen et al proposed that NSE and BE have their origin in the same 
progenitor cell. 113 Most importantly, the rigorous evaluation of the NSE in patients 
that had neoplastic and preneoplastic lesions, showed no genetic abnormalities or 
buried glands, which were proven in the BE epithelium prior to RFA. 114 
However, the finding of the DIS in all NSE biopsy specimens in patients with CR-
IM in the study by Jovov et al warrants further investigation regarding the 
defensive properties of NSE. 74 
Dilated intercellular spaces are generally accepted as the microscopic 
characteristic of GERD. The studies on patients with erosive and non-erosive 
esophagitis, and healthy controls, proved that DIS is present in GERD regardless 
of macroscopic findings. An interesting study by Calabrese et al proved that DIS is 
initiated not only by acid reflux but with bile reflux as well. In their study there were 
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no differences regarding the width of intercellular spaces in GERD patients in 
whom predominant acid or bile reflux was recorded (2.27 ± 0.47 µm in patients 
with pure acid reflux and 2.11 ± 0.23 µm in those with mixed bile/acid reflux). 
Authors indicated that ultrastructural damage of esophageal epithelium may occur 
even with adequate acid suppression therapy, due to the noxious effect of bile 
salts. 115 
The aforementioned study of Jovov et al showed that biopsy samples obtained 
from the level of proximal esophagus had not revealed DIS in the majority of 
patients (11/13). This finding implicated that DIS was present almost exclusively in 
NSE, but not in the untreated proximal esophagus. These findings are not in 
concordance wit the data obtained in the study by Caviglia et al. 116 The authors 
conducted the measurement of intercellular spaces in NERD patients and healthy 
controls in biopsy samples taken from the distal and mid thoracic esophagus. 
Interestingly, in NERD patients, DIS were found equally in distal and proximal 
esophagus, indicating that pharyngeal presentation of reflux in NERD patients may 
be elucidated by this finding. The bottom line of this study may be, that if 
pathologic reflux is present, it will not make ultrastructural damage only at the level 
of distal esophageal segments, but proximal as well.  
The results of our study implicated presence of dilated intercellular spaces in NSE. 
Although there are no standardized data, which could serve as the basis for 
comparison, for each patient proximal healthy esophagus, was also analyzed, and 
the control values were obtained. Mean value of intercellular spaces (IS) length 
obtained from NSE in all patients under PPI regimen was 1.262 ± 0.174 µm, while 
mean length of IS in proximal esophagus in the same group of patients 0.734 ± 
0.325 µm. Mean value of IS length in biopsy specimens of patients who underwent 
LNF was 0.378 ± 0.116 µm and 0.879± 0.329 µm in proximal esophagus and NSE, 
respectively. When comparative analysis was made for each individual patient, 
comparing the values of IS length in NSE and proximal esophagus, statistical 
difference was reached in 5 out of 11 patients. These results implicates that the 
presence of DIS was found in the majority of patients after RFA inside the NSE. 
However, with the lack of standardization, one cannot make an assumption how 
these values should be interpreted, especially when compared to samples of 
proximal esophagus in individual patient. We are usually referring to the IS length 
in the proximal healthy esophagus to be normal. If the values obtained from NSE 
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segment do not differ from proximal, than it is hard to pronounce the presence of 
DIS in that individual patient. But, we also have to be aware that reflux may have 
high extent, which may lead to DIS in proximal esophageal segments. It is our 
opinion that analysis of DIS must be made with reference to proposed cut-off 
value, and certainly not with presumption that length of IS in proximal esophagus 
is normal. 
Comparative analysis of IS lengths in NSE were made between those who 
underwent antireflux surgery, and those receiving PPI’s therapy. The mean IS 
length was statistically significantly smaller in the NSE of the patients who 
underwent antireflux surgery, opposed to those who were treated with PPI’s. In 
accordance to applied cut off value of IS length, all of the 5 patients in the PPI’s 
group were found to have DIS in NSE. Out of 6 analyzed patients in group of 
patients who underwent surgery, 50% had DIS in NSE. Further, significantly higher 
values of mean length of IS values were found in biopsy specimens obtained from 
proximal esophagus of patients inside PPI’s group. This finding may implicate that 
ongoing reflux in these patients does not lead only to DIS in distal, but proximal 
esophagus as well. These data are matched with those presented in the study of 
Caviglia et al in which DIS were confirmed in proximal esophagus of NERD 
patients. 116 
The limitations of the current study are obvious. The first limitation is of course 
limited number of patients, which is directly influenced by the very demanding 
study methodology. This limitation was at least partially overcome with high 
number of data obtained from each biopsy sample. The internal checking of data 
for every biopsy sample was performed with presentation of three-dimensional 
model, which provided the even more valuable data in the term of overall surface 
that IS occupy regarding the whole thickness of epithelium. The second limitation 
is that patients were not stratified according to the baseline characteristics, prior to 
RFA treatment, which could make an impact on the results. 
The conclusion may be as follows. Dilated intercellular spaces are present in NSE, 
but not to that extent earlier described. Further, there is a statistical evidence that 
DIS are present in less extent in those who underwent antireflux surgery after 
RFA, of course more patients and longer follow-up is warranted. Presence of DIS 
in the proximal esophagus of the majority of post RFA patients undergoing 
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continuous PPI’s treatment, even more justifies the hypothesis that ongoing 
weakly acid reflux is the probable etiologic factor behind epithelial damage. 
When these data are combined with those obtained from endoscopic follow-up 
and basic histology, we might get better insight into RFA perspective in the term of 
future treatments protocols.  
It seems to be a necessity to standardize the criteria regarding the post RFA 
treatment, and to provide the straightforward indications for antireflux surgery after 
ablation. Based on our study and the existing literature data, we could make a 
following proposition. 
The patients who should be proposed with antireflux surgery after HALO RFA are 
those with long segment BE, hiatal hernia> 3cm, and those with documented 






































1. Radiofrequency ablation (RFA) is safe and effective procedure in complete 
eradication of Barrett’s esophagus.  
 
2. Patients with Barrett’s esophagus in this group were commonly presented with 
long lasting GERD, hiatal hernia and ineffective esophageal motility, as well as 
insufficient values of lower esophageal sphincter. 
 
3. Patients with dilated distal esophagus, hiatal hernia and those with 
uncontrolled gastroesophageal reflux represent the group in whom complete 
eradication of Barrett’s esophagus is difficult to achieve with RFA, with high 
percentage of residual BE.   
 
4. After the evaluation of the complete sample of patients none of the post RFA 
applied treatment types did not reach the statistical advantage in the term of 
BE recurrence prevention. Nissen fundoplication had significantly better 
protective effect over PPI’s in the group of patients with long segment BE and 
hiatal hernia >3 cm.  
 
5. Electron microscopy is highly efficient in evaluation of morphological structure 
of neosquamous epithelium.  
 
6. Dilated intercellular spaces are present inside neosquamous epithelium, as 
well as in proximal macroscopically healthy esophagus. DIS are present in 
higher extent in those patients undergoing medicamentous treatment opposed 
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List of Abbreviations 
 
 
BE   Barrett’s esophagus 
GER   Gastroesophageal reflux 
GERD   Gastroesophageal reflux disease 
EAC   Esophageal adenocarcinoma 
GI   Gastrointestinal 
BMI   Body mass index 
LNF   Laparoscopic Nissen fundoplication 
LES   Lower esophageal sphincter 
GEJ   Gastroesophageal junction 
SCE   Squamous cell epithelium 
NSCJ   Newly formed squamocolumnar junction 
RFA   Radiofrequency ablation 
NSE   Neosquamous epithelium 
DIS   Dilated intercellular spaces 
IM   Intestinal metaplasia 
LGD   Low grade dysplasia 
HGD   High grade dysplasia 
CE- IM  Complete eradication intestinal metaplasia 
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